Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3598123 A
Publication typeGrant
Publication date10 Aug 1971
Filing date1 Apr 1969
Priority date1 Apr 1969
Publication numberUS 3598123 A, US 3598123A, US-A-3598123, US3598123 A, US3598123A
InventorsAlejandro Zaffaroni
Original AssigneeAlza Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Bandage for administering drugs
US 3598123 A
Images(1)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent [72] Inventor Alejandro Zaflaroni Atherton, C851. [21] Appl. No. 812,117 [22] Filed Apr. 1, 1969 [45] Patented Aug. 10, 1971 [73] Assignee ALZA Corporation [54] BANDAGE FOR ADMINIS'IERING DRUGS 13 Claims, 2 Drawing Figs.

[52] US. Cl 128/268, 424/20, 424/28 [51] Int. Cl. A61! 7/02 [50] FieldoISear-ch 1. 128/155- [56] Referenes Clted UNITED STATES PATENTS 3,249,109 5/1966 Maeth et a1 128/268 3,328,259 6/1967 Anderson 128/156 X 3,339,546 9/1967 Chen 128/156 3,444,858 5/1969 Russell 128/268 X 3,464,413 9/1969 Goldfarb et al.... 128/268 3,520,949 7/1970 Shepherd et al 128/156 UX Primary Examiner-Charles F. Rosenbaum Attorney-Steven D. Goldby PATENTEUAUGIOBII 3,59 ,123

INVENTOR Alejandro Zaffaroni WSW BANDAGE FOR ADMINISTERING DRUGS BACKGROUND OF THE INVENTION This invention relates to a bandage for use in the continuous administration of systemically active drugs.

One primary objective of drug therapy is to achieve a particular (uniform, variable, or modulated) blood level of drug in circulation for a period of time (hours, days, months). Many drugs, such as the steroidal hormones, are absorbed in a relatively short period of time, and are not long acting due to rapid metabolism and excretion following administration. To obtain the desired therapeutic effect, it is necessary in most cases to establish a dosage regime of multiple unit doses over a 24 hour period. Most drugs are administered orally or by injection and neither of these modes of administration achieves the desired blood level of drug in circulation in the typical case.

With oral administration of drugs, it is difficult if not impossible to achieve a constant blood level of drug in circulation. This is true even though the drug is administered at periodic intervals according to a well-defined schedule. One reason for this is that the rate of absorption of drugs through the gastrointestinal tract is affected by the contents of the tract. Such variables as whether the drug is administered before or after eating and the type and quantity of food eaten (for example, high or low fat content) or administered before or after a bowel movement, can control the rate of absorption of the drug in the gastrointestinal tract. As most of the absorption of drugs takes place in the small intestine, the time of passage through the small intestine is another governing factor. This in turn is affected by the rate of peristaltic contracting, adding further uncertainty. Also important is the rate of circulation of blood to the small intestine.

The almost inevitable result of oral administration of drugs through the gastrointestinal tract is that the level of drug in circulation surges to a high each time the drug is administered, followed by a decline in concentration in the blood and body compartments. Thus, a plot of drug in circulation following a dosage schedule of several tablets a day has the appearance of a series of peaks, which may surpass the toxic threshold, and valleys. Each time the blood level decreases below a critical point needed to achieve the desired therapeutic effect that effect will no longer be obtained. Worse still, with antimicrobial drugs, the disease-producing micro-organisms rapidly multiply when the concentration of drug in circulation descends below a critical point. It is likely that the drug-resistant mutant strains which are becoming increasingly prevalent and represent one of the major problems in the therapeutics of infectious diseases are formed precisely at such times.

One approach to this problem has been the advent of the socalled sustained release or time-capsule in oral dosage form. While many of these perform satisfactorily in vitro and in animal or clinical studies under controlled conditions of nutrition and activity, there is little or no evidence that these dosage forms are effective for achieving a continuous and predictable level of drug in circulation over a prolonged period of time under the normal conditions encountered by the outpatient.

Many effective therapeutic agents are destroyed by microbial flora of G.l. secretions or are poorly absorbed in the gastrointestinal tract.

Administration of drugs by injection is inconvenient, painful, and the risk of local tissue reaction and of infection is serious. Moreover, the typical result of administration by injection is a surge in blood level concentration of the drug immediately after injection, followed by a decline and another surge in concentration upon subsequent injections.

Other dosage forms such as rectal suppositories and sublingual lozenges also produce nonuniform levels of the therapeutic agent in circulation. These dosage forms require great patient cooperation, have low patient acceptability, and are sparingly used throughout most of the world.

Dosage forms described above all bring about a pulse entry of drug, that is, a concentrated dose of drug is brought into contact with an organ of entry at a particular time unit. Undoubtedly, this creates drug concentrations beyond the capacity of the active centers to accept (that is, the saturation point is exceeded by many orders of magnitude) and, also, until dilution in body fluids takes place, may exceed the capacity of metabolic and excretory mechanisms. The result is that a toxic level of drug is allowed to build, for a period of time, with detrimental effects for particular tissues or organs. To obtain persistence of effect, the usual industrial approach is to make the initial dose high or to modify the drug structure to obtain a longer metabolic half-life of the drug in circulation long. Raising the initial dosage only worsens the problem. Many derivatives with long half-lives have a lower therapeutic index (ratio between the median toxic dose and the median effective dose) than that of the parent compounds; and therefore these approaches are not the answer to the problem.

To avoid the problems discussed above, it has been suggested that systemically active drugs can be administered through the skin. Percutaneous administration can have the advantage of permitting continuous administration of drug to circulation over a prolonged period of time to obtain a uniform delivery rate and blood level of drug. Commencement and termination of drug therapy are initiated by the application and removal of the dosing device from the skin. Uncertainties of administration through the gastrointestinal tract and the inconvenience of administration by injection are eliminated. Since a high concentration of drug never enters the body, problems of pulse entry are overcome and metabolic half-life is not a factor of controlling importance.

Despite these advantages of administering systemically active drugs through the skin, prior devices designed for this purpose were either impractical or inoperative and did not provide continuous administration and delivery rate. This form of administration has not been accepted by the medical profession and the only prior art manner of obtaining continuous delivery rate remains the continuous intravenous drip.

SUMMARY OF THE INVENTION Accordingly, an object of this invention is to provide a device for the administration of systemically active drugs which overcomes the aforesaid disadvantages inherent in prior art modes of administration.

Another object of this invention is to provide a reliable and easily applied device for continuously administering controlled quantities of systemically active drugs through the skin.

Still another object of this invention is to provide a device for administering systemically active drugs through the oral mucosa.

A further object of this invention is to provide a complete dosage regime for a particular time period, the use of which requires patient intervention only for initiation and termination.

In accomplishing these objects, one feature of this invention resides in a bandage for use in the continuous administration of systemically active drugs by absorption. The bandage is comprised of a backing member bearing a pressure-sensitive adhesive layer on one surface thereof. The pressure-sensitive adhesive has distributed therethrough microcapsules acting as an external drug reservoir and comprising a systemically active drug encapsulated with a material permeable to passage of the drug. The drug is in a form suitable for absorption through the skin or oral mucosa.

Other objects, features, and advantages of the invention will be apparent to those skilled in the art from the detailed description of the invention which follows, and from the drawings.

BRIEF DESCRIPTION OF DRAWINGS In the drawings:

FIG. 1 is a perspective view of the bandage of the invention and FIG. 2 is a cross-sectional view of the bandage of the invention.

As illustrated in FIGS. 1 and 2, the bandage of this invention is comprised of a backing member 11 bearing a pressuresensitive adhesive layer 12 on one surface thereof. Adhesive layer 12 has microcapsules 13 of a systemically active drug encapsulated with a material permeable to passage of the drug uniformly distributed therethrough.

DETAILED DESCRIPTION OF THE INVENTION To use the bandage 10 of the invention, it is applied to the patient's skin. Adhesive layer 12 should be in firm contact with the skin, forming a tight seal therewith. Drug within microcapsules 13, whether in solid form or solution, migrates through the walls of the microcapsules, acting as a solubility membrane, and into adhesive layer 12, as by diffusion. Ordinarily, one would expect the drug migration to cease when sufficient drug has reached the outer surface of microcapsules 13 to create an equilibrium or when adhesive layer 12 has become saturated with the drug. However, when adhesive layer 12 is in contact with the patients skin, drug molecules which are continuously removed from the outer surface of microcapsules l3 migrate through the adhesive to the outer surface of the adhesive layer and are absorbed by the skin. Absorbed drug molecules pass through the skin and enter circulation through the capillary network. While the bandage may be applied to any area of the patients skin, the lower back and buttocks are the areas of choice. In like manner, the bandage can be applied to the mucosa of the mouth, for example, by application to the palate or the buccal mucosa, to obtain absorption of the drug by the oral mucosa. Although obtaining a liquidtight adhesive seal between the skin and bandage is important, it becomes critical in the mouth. Without such a seal, irrigation of the oral mucosa by saliva will transfer the drug to the gastrointestinal tract, rather than to circulation through the oral mucosa.

Those skilled in the art will appreciate that the bandage of this invention significantly differs from prior art wound dressings or bandages containing antiseptics or topically active drugs. The bandage of this invention contains an encapsulated systemically active drug and is applied to unbroken skin, to introduce the drug to circulation in the bloodstream and produce a pharmacologic response at a site remote from the point of application of the bandage. Thus, the bandage functions as an external drug reservoir and provides a complete dosage regime for a particular time period.

In practicing this invention, one can employ any systemically active drug which will be absorbed by the body surface to which the bandage is applied. The term systemically active drug" is used herein in its broadest sense as indicating a substance or composition which will give a pharmacologic response at a site remote from the point of application of the bandage. Of course, the amount of drug necessary to obtain the desired therapeutic effect will vary depending on the particular drug used. Suitable drugs include, without limitation, antimicrobial agents such as penicillin, tetracycline, oxytetracycline, chlortetracycline, chloramphenicol, and sulfonamides; sedatives and hypnotics such as pentabarbital' sodium, phenobarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, carbromal, and sodium phenobarbital; psychic energizers such as 3( Z-aminopropyl) indole acetate and 3-)2-aminobutyl) indole acetate; tranquilizers such as reserpine, chlorpromazine hydrochloride, and thiopropazate hydrochloride; hormones such as adrenocorticosteroids, for example, tia-methylprednisolone, cortisone, cortisol, and triamcinolone; androgenic steroids, for example, methyltestosterone, and fluoxymesterone; estrogenic steroids, for example, estrone, l7B-estrodiol and ethinyl estradiol; progrestational steroids, for example, l7a-hydronyprogesterone acetate, medroxyprogesterone acetate, l9-norprogesterone, and norethindrone; and thyroxine; antipyretics such as aspirin, salicylamide, and sodium salicylatc; antispasmodics such as atropine, mcthscopolaminc bromide, methscopolamine bromide with phenobarbital; antimalarials such as the 4- aminoquinolines, S-aminoguinolines, and pyrimethamine; and nutritional agents such as vitamins, essential amino acids, and essential fats.

Drugs which alone do not pass through the skin or oral mucosa can be dissolved in an absorbable, pharmacologically acceptable solvent to achieve passage through the external body layer. Suitable solvents include alcohols containing 2 to 10 carbon atoms, such as hexanol, cyclohexanol, benzylalcohol, l,2-butanediol, glycerol, and amyl alcohol; hydrocarbons having 5 to 12 carbon atoms such as n-hexane, cyclohexane, and ethyl benzene; aldehydes and ketones having 4 to 10 carbon atoms such as heptyl aldehyde, cyclohexanone, and benzaldehyde; esters having 4 to 10 carbon atoms such as amyl acetate and benzyl propionate; ethereal oils such as oil of eucalyptus, oil of rue, cumin oil, limonene, thymol, and lpinene; halogenated hydrocarbons having two to eight carbon atoms such as n-hyxyl chloride, n-hyxyl bromide, and cyclohexyl chlorides; or mixtures of any of the foregoing solvents. Also, with drugs which do not pass through the skin or oral mucosa, simple pharmacologically acceptable derivatives of the drugs, such as ethers, esters, amides, acetals, etc. having the desired absorption property can be prepared and used in practicing the invention. Of course, the derivatives should be such as to convert to the active drugs within the body through the action of body enzyme assisted transformations, PH, etc.

Materials used to encapsulate the drug or drug solution and form the microcapsules to be distributed throughout the adhesive must be permeable to the drug to permit passage of the drug, as by difiusion, through the walls of the microcapsules at a relatively low rate. Normally, the rate of passage of the drug through the walls of the microcapsules is dependent on the solubility of the drug or drug solution therein, as well as on the microcapsule wall thickness. This means that selection of appropriate encapsulating materials will be dependent on the particular drug used in the bandage. By varying the encapsulating material and the wall thickness, the dosage rate per area of bandage can be controlled.

One presently preferred class of encapsulating materials are the organopolysiloxane rubbers, commonly known as silicone rubbers. Suitable silicone rubbers are the conventional heatcurable silicone rubbers and the room-temperature-vulcanizable silicone rubbers.

Conventional silicone rubbers which are converted to the rubbery state by the action of heat are predominantly linear organopolysiloxanes having an average degree of substitution of about two organic groups attached directly to silicon per silicon atom. Preferably, the organic groups are monovalent hydrocarbon radicals such as alkyl, aryl, alkenyl, alkaryl, aralkyl, and of these, the methyl, phenyl and vinyl radicals are most preferred.

Variation of the organic groups in the silicone rubber can be used to vary the solubility of the drug in the polymer and hence can control the speed of the migration of the drug through the polymer. Also, drugs which are insoluble in one type of silicone rubber may be soluble in a different type of polymer. One especially preferred class of silicone polymers are the pure dimethylpolysiloxanes.

Room-temperature-vulcanizable silicone rubbers are also commercially available and are known to the art. In general, they employ the same silicone polymers as discussed above although the polymers often contain a greater amount of silicon-bonded hydroxy groups. This type of silicone rubber will cure at room temperature in the presence of an appropriate catalyst, such as stannous 2-ethylhexoate.

Exemplary patents disclosing the preparation of silicone rubbers are U.S. Pat. Nos. 2,54l,l37, 2,723,966, 2,863,846, 2,890,188, 2,927,907, 3,002,951, and 3,035,016.

Another class of materials suitable for encapsulating drugs are the hydrophilic polymers of monoesters of an olefinic acid, such as acrylic acid and mcthacrylic acid. Exemplary polymers of this class include poly (hydroxyethylacrylatc) and poly (hydronyethylmethacrylatc). These polymers are commercially available and their preparation is described in U.S. Pat. Nos. 2,976,576 and 3,220,960, as well as in Belgian Pat. No. 701,813. When using these hydrophilic polymers, the drug is normally dissolved in a solvent such as a lower alcohol to promote passage of the drug through the polymer.

Other exemplary materials for use as encapsulating media in this invention include polyvinylalcohol, polyvinylacetate, plasticized polyvinylchloride, plasticized nylon, collagen, modified collagen, gelatin, and waxes such as polyethylene wax, oxidized polyethylene wax, hydrogenated castor oil, etc.

To provide the microcapsules, the encapsulating materials can be uniformly impregnated with the drug or drug solution to form microcapsules which are a matrix having the drug distributed therethrough. Alternatively, particles or solutions of drugs can be encapsulated with thin coatings of the encapsulating material to form microcapsules having an interior chamber containing the drug. If desired, particles of a matrix, such as starch, gum acacia, gum tragacanth, and polyvinylchloride, can be impregnated with the drug and encapsulated with another material such as the encapsulating materials previously discussed which function as a solubility membrane to meter the flow of drug to the adhesives; use of a matrix and a different solubility membrane can slow the passage of the drug from the microcapsules which is desirable with drugs that are released too rapidly from available encapsulating materials. In contrast, by encapsulating a solution of the drug, the solvent speeds passage of the drug through the microcapsule walls.

Any of the encapsulation or impregnation techniques known in the art can be used to prepare the microcapsules to be incorporated into the adhesive base in accord with this invention. Thus, the drug or drug solution can be added to the encapsulating material in liquid form and uniformly distributed therethrough by mixing; or solid encapsulating material can be impregnated with the drug by immersion in a bath of the drug to cause the drug to diffuse into the material. Subsequently, the solid material can be reduced to fine microcapsules by grinding, each of the microcapsules comprising drug coated with and distributed throughout the encapsulating material. Alternatively, fine particles or solutions of the drug can be encapsulated with a coating. One suitable technique comprises suspending dry particles of the drug in an airstream and contacting that stream with a stream containing the encapsulating material to coat the drug particles. Usually, the microcapsules have an average particle size of from 1 to 1,000 microns, although this is not critical to the invention.

The microcapsules, however made, are then mixed with a pressure-sensitive adhesive. Any of the well-known dermatologically acceptable pressure-sensitive adhesives which permit drug migration can be used in practicing this invention. Exemplary adhesives include acrylic resins such as polymers of esters of acrylic acid with alcohols such as n-butanol, n-pentanol, isopentanol, Z-methyl butanol, l-methyl butanol, l-methyl pentanol, 2-methyl pentanol, 3-methyl pentanol, 2-ethyl butanol, isooctanol, n-deconal, or n-dodecanol, alone or copolymerized with ethylenically unsaturated monomers such as acrylic acid, methacrylic acid, acrylamide, methacrylamide, N-alkoxymethyl acrylamides, N-alkoxymethyl methacrylamides, N-tert. butylacrylamide, itaconic acid, vinylacetate, N-branched alkyl maleamic acids wherein the alkyl group has to 24 carbon atoms, glycol diacrylates. or mixtures of these; elastomeric silicone polymers; polyurethane elastomers; rubbery polymers, such as polyisobutylene, polyisoprene, and polybutadiene; vinyl polymers, such as polyvinylalcohol, polyvinyl pyrrolidone, and polyvinylacetate; cellulose derivatives such as ethyl cellulose, methyl cellulose, and carboxymethyl cellulose; natural gums such as guar, acacia, pectins, etc. For use in contact with the oral mucosa rubbery. polymers, such as polyisobutylene, with or without gum modifiers gives good results, as do polyvinyl alcohol, polyvinyl pyrrolidone, cellulose derivatives and others. The adhesive-s may be compounded with tackifiers and stabilizers as is well known in the art.

The mixture of microcapsules and pressure-sensitive adhesive is then coated onto a backing member, usually to provide an adhesive layer 0.01 to 7 millimeters thick, although these limits can be exceeded if more or less drug is required. The purpose of the backing is to provide support for the bandage and to prevent passage of the drug through the adhesive surface away from the body surface to which the bandage is applied. Backing members can be flexible or nonflexible and suitable materials include cellophane, cellulose acetate, ethyl cellulose, plasticized vinyl acetate-vinyl chloride copolymers, polyethylene terephthalate, nylon, polyethylene, polyvinylidene chloride, coated flexible fibrous backings such as paper and cloth, and aluminum foil.

The required surface area of the bandage will depend on the activity of the drug and the rate of its absorption through the skin. Usually, the adhesive face of the bandage has a surface area of 0.5 to 400 square centimeters, although smaller or larger bandages can be used.

It will be appreciated that on encapsulating the drug with a material, such as silicone rubber, the drug immediately begins to migrate into and through the encapsulating material. On mixing the microcapsules with the adhesive the drug passing through the walls of the microcapsules will enter the adhesive, eventually saturating the adhesive with the drug. To prevent passage of the drug away from the exposed surface of the adhesive prior to use, the adhesive surface of the bandage generally is covered with a protective release film or foil, such as waxed paper, prior to use. Alternatively, the exposed rear surface of the backing member can be coated with a low-adhesion backsize and the bandage rolled about itself.

The following examples will serve to illustrate the invention without in any way being limiting thereon.

EXAMPLE I 2-hydroxyethyl methacrylate grams) is mixed with tertiary butyl peroctoate (0.20 gram). Ethylene glycol dimethacrylate (0.20 gram) is added along with 4 grams of sodium bicarbonate as a foaming agent. The mixture is heated to 70 C. and the resulting solid, firable polymeric foam is ground into fine powder of 20-micron average particle size. The polymeric powder (10 grams) is mixed with chloramphenicol antibiotic (2 grams) dissolved in ethyl alcohol and the resultant mixture placed on a mechanical roller until the polymeric powder has absorbed the antibiotic. The solution is then filtered.

The resulting microcapsules of chloramphenical antibiotic are mixed with 100 grams of a 22 percent solution in heptaneisopropylalcohol (70:30) of a rubbery copolymer of isooctyl acrylate and acrylic acid (94:6) adhesive to uniformly distribute the microcapsules through the adhesive solution. The resulting slurry is coated onto a cellophane sheet l0 centimeters in width by 10 centimeters in length and the solvent removed by evaporation.

When applied to the skin of a subject, the resulting bandage is effective to administer chloramphenicol antibiotic through the skin to circulation to provide a continuous administration of the daily dose of the antibiotic.

EXAMPLE ll Liquid dimethyl silicone rubber (100 grams, Dow-coming Silastic) is mixed with finely divided crystalline megesterol acetate (5 grams). After uniformly mixing the hormone with the unvulcanized silicone rubber, 0.5 gram of stannous octoate catalyst is added and the rubber cured at room temperature. The resulting silicone rubber body is reduced to an average particle size of 100 microns.

5 grams of the resulting encapsulated megesterol acetate are mixed with an elastomeric silicone pressure-sensitive adhesive 10 grams) to uniformly distribute the microcapsules throughout the adhesive. Immediately thereafter, the adhesive mixture is coated onto one surface of a IOO-square centimeter. Mylar sheet. The resulting bandage is used for fertility regulation.

Thus, this invention provides an easy to use device for administering systemically active drugs through the skin and oral mucosa. Uncertainties of administration through the gastrointestinal tract are avoided and a constant level of drug in circulation can be obtained. Treatment is begun by applying the bandage to the skin or oral mucosa and terminated by removing it therefrom. The bandage can contain and administer the complete dosage requirements for a particular time period, for example, for 24 hours. Intervention by the patient is required only to apply and remove the bandage, so that uncertainties are eliminated.

While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiment, it will be understood that various omissions and substitutions and changes in the form and details of the bandage illustrated may be made by those skilled in the art without departing from the spirit of the invention. It is the intention, therefore, to be limited only as indicated by the scope of the following claims.

What I claim is:

1. A medical bandage for use in the continuous administration to circulation of controlled quantities of systemically active drugs over a prolonged period of time by absorption through the external body skin or mucosa, said bandage comprising (l) a backing member bearing (2) a pressure-sensitive adhesive on one surface thereof, said pressure-sensitive adhesive having distributed therethrough (3) a plurality of discrete microcapsules, each of which microcapsules comprising a systemically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of drug from the said microcapsules to the skin or mucosa at a controlled and predetermined rate over a prolonged period of time.

2. The bandage as defined by claim 1, wherein each of said microcapsules (3) is comprised of systemically active drug formulation microencapsulated with the said drug release rate controlling wall material.

3. The bandage as defined by claim 1, wherein each of said microcapsules (3) is comprised of a matrix of the drug release rate controlling wall material, said matrix having the systemically active drug formulation distributed therethrough.

4. The bandage as defined by claim 1, wherein the systemically active drug formulation is soluble in the drug release rate controlling material.

5. The bandage as defined by claim 1, wherein the pressuresensitive adhesive is permeable to passage of the systemically active drug formulation.

6. The bandage as defined by claim I, wherein the drug formulation comprises a pharrnacologically acceptable solvent.

7. The bandage as defined by claim 1, wherein said drug release rate controlling material is silicone rubber.

8. The bandage as defined by claim 1, wherein said drug release rate controlling material is a hydrophilic polymer of an ester of an olefinic acid.

9. The bandage as defined by claim 1, wherein the pressuresensitive adhesive is adapted to provide a liquidtight adhesive seal between the skin or mucosa and the bandage.

10. The bandage as defined by claim 1, wherein the surface of a pressure-sensitive adhesive 3) is covered with a protective release coating (4).

11. The bandage as defined by claim 1, wherein the outer surface of the backing member l) is coated with a low adhesion backsize (5).

12. The bandage as defined by claim 1, wherein said microcapsules have an average particle size of from 1 to 1,000 microns.

13. The bandage as defined by claim 1, wherein the adhesive face of the bandage has an area of 0.5 to 400 square centimeters.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3249109 *1 Nov 19633 May 1966Maeth HarryTopical dressing
US3328259 *8 Jan 196427 Jun 1967Parachem CorpDressing for a wound containing a hemostatic agent and method of treating a wound
US3339546 *13 Dec 19635 Sep 1967Squibb & Sons IncBandage for adhering to moist surfaces
US3444858 *11 May 196620 May 1969Higham S RussellMethod and means for administering drugs
US3464413 *26 May 19672 Sep 1969United Merchants & MfgMedical bandages
US3520949 *26 Jul 196621 Jul 1970Nat Patent Dev CorpHydrophilic polymers,articles and methods of making same
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3731683 *4 Jun 19718 May 1973Alza CorpBandage for the controlled metering of topical drugs to the skin
US3797494 *9 Aug 197119 Mar 1974Alza CorpBandage for the administration of drug by controlled metering through microporous materials
US3828777 *8 Nov 197113 Aug 1974Alza CorpMicroporous ocular device
US3901232 *26 Oct 197326 Aug 1975Alza CorpIntegrated device for administering beneficial drug at programmed rate
US3911099 *23 Jan 19747 Oct 1975Defoney Brenman Mayes & BaronLong-acting articles for oral delivery and process
US3921636 *22 Apr 197425 Nov 1975Alza CorpNovel drug delivery device
US3951622 *4 Dec 197420 Apr 1976Wilk Immanuel JTime release perfume method and device
US3960150 *15 Sep 19751 Jun 1976Alza CorporationBioerodible ocular device
US3961628 *21 Apr 19758 Jun 1976Alza CorporationOcular drug dispensing system
US3972995 *14 Apr 19753 Aug 1976American Home Products CorporationDosage form
US3981303 *31 Jul 197521 Sep 1976Alza CorporationBioerodible ocular device
US3986510 *1 Aug 197519 Oct 1976Alza CorporationBioerodible ocular device
US3993071 *24 Jul 197523 Nov 1976Alza CorporationBioerodible ocular device
US3993073 *3 Mar 197523 Nov 1976Alza CorporationNovel drug delivery device
US3996934 *9 Aug 197114 Dec 1976Alza CorporationMedical bandage
US4026290 *18 Nov 197531 May 1977Fisons LimitedMethod of administering medicaments through the skin
US4031894 *7 Sep 197628 Jun 1977Alza CorporationBandage for transdermally administering scopolamine to prevent nausea
US4039653 *21 Jul 19752 Aug 1977Defoney, Brenman, Mayes & BaronLong-acting articles for oral delivery and process
US4186743 *28 Feb 19785 Feb 1980Personal Products CompanyPerfuming self-adhering napkins
US4210633 *20 Oct 19781 Jul 1980Eli Lilly And CompanyFlurandrenolide film formulation
US4291014 *11 Jul 198022 Sep 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing estradiol diacetate
US4291015 *26 Jun 198022 Sep 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing a vasodilator
US4292301 *9 Jul 198029 Sep 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing ephedrine
US4292302 *9 Jul 198029 Sep 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing terbutaline
US4292303 *9 Jul 198029 Sep 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing clonidine
US4294820 *9 Jul 198013 Oct 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing phenylephrine
US4310509 *31 Jul 197912 Jan 1982Minnesota Mining And Manufacturing CompanyPressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4321252 *17 Dec 198023 Mar 1982Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing ester derivatives of estradiol
US4323557 *31 Jul 19796 Apr 1982Minnesota Mining & Manufacturing CompanyPressure-sensitive adhesive containing iodine
US4329333 *24 Nov 198011 May 1982Arthur BarrMethod for the oral treatment of dogs and other animals
US4336243 *4 May 198122 Jun 1982G. D. Searle & Co.Transdermal nitroglycerin pad
US4340043 *15 Nov 197920 Jul 1982Smith & Nephew Research Ltd.Adhesive-coated sheet material incorporating anti-bacterial substances
US4409206 *14 Aug 198111 Oct 1983Boehringer Ingelheim GmbhTransdermal release system for pharmaceutical preparation
US4455146 *2 Mar 198219 Jun 1984Hisamitsu Pharmaceutical Co., Ltd.Novel plasters
US4460369 *21 Dec 198117 Jul 1984Smith & Nephew Research Ltd.Adhesive-coated sheet material incorporating anti-bacterial substances
US4460562 *30 Mar 198317 Jul 1984Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing propranolol
US4492685 *30 Jan 19848 Jan 1985Key Pharmaceuticals, Inc.Protective skin matrix
US4563184 *17 Oct 19837 Jan 1986Bernard KorolSynthetic resin wound dressing and method of treatment using same
US4564010 *18 Apr 198414 Jan 1986Daubert Coated Products Inc.Pressure sensitive adhesive film for medical use
US4568343 *9 Oct 19844 Feb 1986Alza CorporationSkin permeation enhancer compositions
US4597961 *23 Jan 19851 Jul 1986Etscorn Frank TTranscutaneous application of nicotine
US4614787 *13 Nov 198430 Sep 1986Thermedics, Inc.Drug dispensing wound dressing
US4631227 *5 Dec 198323 Dec 1986Kenji NakamuraToilet article
US4638043 *23 Aug 198520 Jan 1987Thermedics, Inc.Drug release system
US4666441 *17 Dec 198519 May 1987Ciba-Geigy CorporationMulticompartmentalized transdermal patches
US4667032 *10 Oct 198519 May 1987Merck Frosst Canada, Inc.Phenothiazone derivatives and analogs
US4690683 *2 Jul 19851 Sep 1987Rutgers, The State University Of New JerseyTransdermal varapamil delivery device
US4719226 *31 Dec 198412 Jan 1988Nitto Electric Industrial Co., Ltd.Percutaneous absorption type preparation and process for preparing the same
US4727868 *20 May 19871 Mar 1988Thermedics, Inc.Anisotropic wound dressing
US4738848 *4 Jun 198619 Apr 1988Nitto Electric Industrial Co., Ltd.Anti-inflammatory analgesic adhesive preparation
US4743249 *10 Jun 198710 May 1988Ciba-Geigy Corp.Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4746515 *26 Feb 198724 May 1988Alza CorporationSkin permeation enhancer compositions using glycerol monolaurate
US4751133 *11 May 198714 Jun 1988Thermedics, Inc.Medical patches and processes for producing same
US4755384 *15 Mar 19845 Jul 1988Kozponti Valto- es Hitelbank RT, Innovacious AlapExternally applied antispasmatic products
US4764362 *22 Oct 198616 Aug 1988The Cook Bates CompanyNail-conditioning emery boards and process for making them
US4764379 *24 Aug 198716 Aug 1988Alza CorporationTransdermal drug delivery device with dual permeation enhancers
US4777046 *1 Oct 198511 Oct 1988Nippon Kayaku Kabushiki KaishaSheet-like preparation
US4781924 *9 Nov 19871 Nov 1988Alza CorporationTransdermal drug delivery device
US4788062 *26 Feb 198729 Nov 1988Alza CorporationTransdermal administration of progesterone, estradiol esters, and mixtures thereof
US4812305 *9 Nov 198714 Mar 1989Vocal Rodolfo SWell medicine strip
US4813976 *7 Apr 198821 Mar 1989The Cook Bates CompanyNail-conditioning emery boards and process for making them
US4816258 *26 Feb 198728 Mar 1989Alza CorporationTransdermal contraceptive formulations
US4820720 *29 Mar 198811 Apr 1989Alza CorporationTransdermal drug composition with dual permeation enhancers
US4834979 *14 Dec 198730 May 1989Alza CorporationMedical bandage for administering beneficial drug
US4837027 *9 Aug 19886 Jun 1989Alza CorporationTransdermal drug delivery device
US4839174 *5 Oct 198713 Jun 1989Pharmetrix CorporationNovel transdermal nicotine patch
US4859667 *14 Jan 198722 Aug 1989Merck Frosst Canada, Inc.Pharmaceutical compositions of phenothiazone derivatives and analogs
US4863738 *23 Nov 19875 Sep 1989Alza CorporationSkin permeation enhancer compositions using glycerol monooleate
US4865848 *26 Feb 198712 Sep 1989Alza CorporationSkin permeation enhancer compositions using sucrose esters
US4879275 *27 May 19887 Nov 1989Nelson Research & Development Co.Penetration enhancers for transdermal delivery of systemic agent
US4880690 *9 Sep 198814 Nov 1989Thermedics, Inc.Perfume patch
US4885154 *1 Mar 19885 Dec 1989Alza CorporationMethod for reducing sensitization or irritation in transdermal drug delivery and means therefor
US4906475 *16 Feb 19886 Mar 1990Paco Pharmaceutical ServicesEstradiol transdermal delivery system
US4908027 *12 Sep 198613 Mar 1990Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US4917688 *27 Jun 198817 Apr 1990Nelson Research & Development Co.Bandage for transdermal delivery of systemically-active drug
US4917895 *14 Jul 198817 Apr 1990Alza CorporationTransdermal drug delivery device
US4920101 *30 Sep 198724 Apr 1990Nelson Research & Development Co.Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4940586 *13 Oct 198810 Jul 1990Alza CorporationSkin permeation enhancer compositions using sucrose esters
US4943435 *28 Oct 198824 Jul 1990Pharmetrix CorporationProlonged activity nicotine patch
US4956171 *21 Jul 198911 Sep 1990Paco Pharmaceutical Services, Inc.Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US4959208 *28 Oct 198825 Sep 1990Ppg Industries, Inc.Active agent delivery device
US4969871 *15 Feb 198913 Nov 1990Alza CorporationIntravenous system for delivering a beneficial agent
US4973468 *22 Mar 198927 Nov 1990Cygnus Research CorporationSkin permeation enhancer compositions
US4985016 *15 Feb 198915 Jan 1991Alza CorporationIntravenous system for delivering a beneficial agent
US5000956 *8 Jul 198819 Mar 1991Alza CorporationPrevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US5004610 *14 Jun 19902 Apr 1991Alza CorporationSubsaturated nicotine transdermal therapeutic system
US5026556 *10 Nov 198825 Jun 1991Norwich Eaton Pharmaceuticals, Inc.Compositions for the transdermal delivery of pharmaceutical actives
US5034386 *17 Aug 198823 Jul 1991Whitby Research, Inc.Methods for administration using 1-substituted azacycloalkanes
US5035886 *10 May 199030 Jul 1991Ppg Industries, Inc.Active agent delivery device
US5045059 *15 Aug 19903 Sep 1991Alza CorporationIntravenous system for delivering a beneficial agent
US5049387 *9 Jun 198917 Sep 1991Alza CorporationInducing skin tolerance to a sensitizing drug
US5053227 *12 Jun 19901 Oct 1991Cygnus Therapeutic SystemsSkin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059189 *8 Sep 198722 Oct 1991E. R. Squibb & Sons, Inc.Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US5059426 *12 Jun 199022 Oct 1991Cygnus Therapeutic SystemsSkin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5061106 *6 Nov 198929 Oct 1991Colgate-Palmolive CompanyToothbrush with slow release of disinfectant and antibacterial agents and method of manufacturing the same
US5068226 *30 Apr 199026 Nov 1991Cyclex, Inc.Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5071645 *20 Mar 199110 Dec 1991Ppg Industries, Inc.Process of producing an active agent delivery device
US5071657 *31 Aug 199010 Dec 1991Schering AktiengesellschaftDevice for transdermal administration of active medicinal agents
US5077054 *27 Nov 199031 Dec 1991Alza CorporationPrevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US5104899 *13 Aug 199014 Apr 1992Sepracor, Inc.Methods and compositions for treating depression using optically pure fluoxetine
US5118509 *30 Aug 19912 Jun 1992Alza CorporationInducing skin tolerance to a sensitizing drug
US5120545 *3 Aug 19909 Jun 1992Alza CorporationReduction or prevention of sensitization to drugs
US5124157 *18 Aug 198923 Jun 1992Cygnus Therapeutic SystemsMethod and device for administering dexmedetomidine transdermally
US5130139 *6 Jul 199014 Jul 1992Alza CorporationReduction or prevention of skin irritation by drugs
US5133970 *11 Jul 199028 Jul 1992Rohm Gmbh Chemische FabrikWater-soluble pressure-sensitive skin-adhesive and use thereof
US5149539 *15 Nov 199122 Sep 1992Alza CorporationReduction or prevention of sensitization to drugs
US5160320 *14 Feb 19903 Nov 1992Alza CorporationIntravenous system for delivering a beneficial agent
US5160741 *13 Nov 19913 Nov 1992Alza CorporationReduction or prevention of skin irritation by drugs
US5171576 *30 Aug 199115 Dec 1992Alza CorporationPrevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US5173302 *28 Sep 199022 Dec 1992Medtronic, Inc.Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
US5189986 *23 Sep 19912 Mar 1993Alza CorporationVeterinary transdermal active agent delivery device
US5198223 *9 Mar 199230 Mar 1993Alza CorporationTransdermal formulations, methods and devices
US5203768 *24 Jul 199120 Apr 1993Alza CorporationTransdermal delivery device
US5204339 *6 Aug 199020 Apr 1993Whitby Research, Inc.Penetration enhancers for transdermal delivery of systemic agents
US5217718 *17 Sep 19918 Jun 1993Cygnus Therapeutic SystemsMethod and device for administering dexmedetomidine transdermally
US5223261 *31 Dec 199129 Jun 1993Riker Laboratories, Inc.Transdermal estradiol delivery system
US5225199 *23 Apr 19916 Jul 1993Teijin LimitedPharmaceutical plasters
US5234690 *23 Aug 199110 Aug 1993Cygnus Therapeutic SystemsTransdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5250028 *9 Aug 19915 Oct 1993Alza CorporationIntravenous system for delivering a beneficial agent using permeability enhancers
US5268179 *14 Feb 19927 Dec 1993Ciba-Geigy CorporationUltrasonically sealed transdermal drug delivery systems
US5273755 *23 Aug 199128 Dec 1993Cygnus Therapeutic SystemsTransdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5273756 *23 Aug 199128 Dec 1993Cygnus Therapeutic SystemsTransdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5284660 *21 Aug 19928 Feb 1994Alza CorporationDelayed onset transdermal delivery device
US5286491 *18 May 199215 Feb 1994Alza CorporationPrevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US5304379 *3 Nov 199219 Apr 1994Alza CorporationMethod for reducing sensitization or irritation in transdermal drug delivery and means therefor
US5314694 *26 Mar 199324 May 1994Alza CorporationTransdermal formulations, methods and devices
US5320850 *12 Feb 199314 Jun 1994Alza CorporationTransdermal delivery of the gestogen ST-1435 and devices therefor
US5342623 *18 Jun 199330 Aug 1994Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US5364634 *8 Nov 199115 Nov 1994Southwest Research InstituteControlled-release PH sensitive capsule and adhesive system and method
US5376377 *17 Dec 199227 Dec 1994Alza CorporationTransdermal contraceptive formulations, methods and devices
US5378730 *3 Dec 19923 Jan 1995Alza CorporationPermeation enhancer comprising ethanol and monoglycerides
US5402777 *3 Jun 19924 Apr 1995Alza CorporationMethods and devices for facilitated non-invasive oxygen monitoring
US5410054 *20 Jul 199325 Apr 1995Merck Frosst Canada, Inc.Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5411740 *8 Feb 19942 May 1995Alza CorporationTransdermal administration of oxybutynin
US5422118 *21 Sep 19926 Jun 1995Pure Pac, Inc.Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5451407 *21 Jun 199319 Sep 1995Alza CorporationReduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5464387 *27 Oct 19947 Nov 1995Alza CorporationTransdermal delivery device
US5500222 *15 Feb 199519 Mar 1996Alza CorporationTransdermal administration of oxybutynin
US5508038 *16 Apr 199016 Apr 1996Alza CorporationPolyisobutylene adhesives for transdermal devices
US5508039 *16 Oct 199216 Apr 1996Alza CorporationControlled transdermal administration of melatonin
US5512292 *21 Dec 199430 Apr 1996Alza CorporationTransdermal contraceptive formulations methods and devices
US5589511 *15 Apr 199431 Dec 1996Sepracor Inc.Method for treating migraine headaches using optically pure S(+) fluoxetine
US5633008 *12 Aug 199327 May 1997Osborne; James L.Method of administering nicotine transdermally
US5633009 *12 Nov 199327 May 1997Sano CorporationTransdermal administration of azapirones
US5641504 *20 May 199224 Jun 1997Alza CorporationSkin permeation enhancer compositions using glycerol monolinoleate
US5648396 *7 Jun 199515 Jul 1997Sepracor Inc.Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
US5662928 *21 Apr 19952 Sep 1997Ciba-Geigy CorporationMethod for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
US5691377 *14 Jul 199425 Nov 1997The United States Of America As Represented By The Secretary Of AgricultureUse of N-methyl-aspartic acid for enhancing growth and altering body composition
US5700478 *19 Aug 199423 Dec 1997Cygnus, Inc.Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5707663 *16 May 199513 Jan 1998Alza CorporationSustained antiepileptic therapy
US5708035 *22 May 199513 Jan 1998Mclean HospitalMethods of use and compositions of R(-) fluoxetine
US5733255 *15 Oct 199631 Mar 1998Novartis Finance CorporationThermopile powered transdermal drug delivery device
US5747065 *29 Sep 19945 May 1998Lee; Eun SooMonoglyceride/lactate ester permeation enhancer for oxybutynin
US5750137 *29 Sep 199412 May 1998Taskovich; Lina TormenMonoglyceride/lactate ester permeation enhancer
US5785991 *7 Jun 199528 Jul 1998Alza CorporationSkin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5817331 *7 Jun 19956 Oct 1998Sano CorporationTransdermal administration of azapirones
US5820876 *6 Jun 199513 Oct 1998Lts Lohmann Therapie-Systeme Gmbh & Co. KgTransdermal therapeutic system
US5837280 *7 Jun 199517 Nov 1998Sano CorporationTransdermal administration of azapirones
US5840327 *15 Aug 199624 Nov 1998Alza CorporationTransdermal drug delivery device having enhanced adhesion
US5843468 *13 May 19961 Dec 1998Alza CorporationSkin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5882675 *7 Mar 199716 Mar 1999Nitto Denko CorporationPercutaneous absorption preparation
US5882676 *26 May 199516 Mar 1999Alza CorporationSkin permeation enhancer compositions using acyl lactylates
US5891868 *21 Nov 19976 Apr 1999Berlex LaboratoriesMethods for treating postmenopausal women using ultra-low doses of estrogen
US5900250 *30 Apr 19984 May 1999Alza CorporationMonoglyceride/lactate ester permeation enhancer for oxybutnin
US5919478 *24 Jun 19946 Jul 1999Alza CorporationIncorporating poly-N-vinyl amide in a transdermal system
US5939426 *28 Feb 199717 Aug 1999Sepracor Inc.Methods for treating urinary incontinence using descarboethoxyloratadine
US5962464 *6 Jul 19985 Oct 1999Sepracor Inc.Methods and compositions for treating allergic asthma using descarboethoxyloratadine
US5980943 *21 Oct 19979 Nov 1999Alza CorporationSustained antiepileptic therapy
US6001390 *18 Dec 199614 Dec 1999Alza CorporationFormulations for transdermal delivery of pergolide
US6004578 *23 Oct 199721 Dec 1999Alza CorporationPermeation enhances for transdermal drug delivery compositions, devices and methods
US6007837 *3 Feb 199928 Dec 1999Alza CorporationDrug delivery devices and process of manufacture
US6054463 *17 Mar 199925 Apr 2000Sepracor Inc.Methods for treating dermatitis using descarboethoxyloratadine
US6100274 *7 Jul 19998 Aug 2000Schering Corporation8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6110488 *6 Jun 199529 Aug 2000Lts Lohmann Therapie-Systeme Gmbh & Co. KgTransdermal therapeutic system, its use and production process
US6110499 *20 Jul 199829 Aug 2000Alza CorporationPhenytoin therapy
US6110973 *28 Jan 199929 Aug 2000SepracorMethods for treating obesity and weight gain using optically pure (-)-bupropion
US6114346 *22 Oct 19995 Sep 2000Schering CorporationTreating sleep disorders using desloratadine
US6126963 *6 Jun 19953 Oct 2000Lts Lohmann Therapie-Systeme Gmbh & Co. KgTransdermal therapeutic system, its use and production process
US6139868 *6 Jun 199531 Oct 2000Lts Lohmann Therapie-Systeme Gmbh & Co. KgTransdermal therapeutic system, its use and production process
US6165497 *1 Mar 199126 Dec 2000Alza CorporationSubsaturated nicotine transdermal therapeutic system
US61745453 Feb 199916 Jan 2001Alza CorporationDrug delivery devices and process of manufacture
US6190683 *28 Aug 199720 Feb 2001Lintec CorporationBlackhead-removing face pack sheet
US619778826 Nov 19986 Mar 2001Vernalis Research Limited(−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US62038175 Jun 199820 Mar 2001Alza CorporationReduction of skin reactions caused by transdermal drug delivery
US62387005 May 199829 May 2001Alza CorporationMethod for preventing crystal formation in a dispersion of a liquid in a matrix
US62654143 May 200024 Jul 2001Schering CorporationTreating sleep disorders using desloratadine
US626798417 Dec 199831 Jul 2001Alza CorporationSkin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
US627788720 Apr 200021 Aug 2001Sepracor, Inc.Methods for treating Parkinson's disease using optically pure (−)-bupropion
US628759828 May 199311 Sep 2001Alza CorporationMethod for providing sustained antiepileptic therapy
US6312715 *1 May 19986 Nov 20013M Innovative Properties CompanyAdhesive microsphere drug delivery composition
US633157111 Aug 199918 Dec 2001Sepracor, Inc.Methods of treating and preventing attention deficit disorders
US633732818 Aug 20008 Jan 2002Sepracor, Inc.Bupropion metabolites and methods of use
US633910614 Sep 200015 Jan 2002Sepracor, Inc.Methods and compositions for the treatment and prevention of sexual dysfunction
US634249622 Feb 200029 Jan 2002Sepracor Inc.Bupropion metabolites and methods of use
US634253330 Nov 199929 Jan 2002Sepracor, Inc.Derivatives of (−)-venlafaxine and methods of preparing and using the same
US634821010 Nov 199919 Feb 2002Alza CorporationMethods for transdermal drug administration
US636911327 Jun 20019 Apr 2002Sepracor, Inc.Method for treating depression using optically pure (−)-bupropion
US639982611 Jan 20004 Jun 2002Sepracor Inc.Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US641005210 Aug 200025 Jun 2002Purdue Research FoundationTea catechins in sustained release formulations as cancer specific proliferation inhibitors
US642881817 Aug 20006 Aug 2002Purdue Research FoundationTea catechin formulations and processes for making same
US64324461 Feb 200113 Aug 2002Bridge Pharma, Inc.Non-arrhythmogenic metabolite of oxybutynin
US644045727 May 199327 Aug 2002Alza CorporationMethod of administering antidepressant dosage form
US645186019 Feb 200217 Sep 2002Sepracor, Inc.Methods for treating depression and other disorders using optically pure (−)-bupropion
US645837428 Jan 19991 Oct 2002Sepracor, Inc.Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
US647607829 Jan 20015 Nov 2002Sepracor, Inc.Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6479073 *7 Oct 199612 Nov 20023M Innovative Properties CompanyPressure sensitive adhesive articles and methods for preparing same
US649560513 Mar 200117 Dec 2002Sepracor Inc.Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion
US651201014 Jul 199728 Jan 2003Alza CorporationFormulations for the administration of fluoxetine
US65380344 Dec 200125 Mar 2003Thomas P. JerussiMethods of treating or preventing weight gain, obesity, and related disorders
US654808229 Feb 200015 Apr 2003Sepracor Inc.Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US655918815 Sep 20006 May 2003Novartis AgMethod of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US65623577 Jun 199913 May 2003Lintec CorporationBlackhead removing sheet and method for producing blackhead removing sheet
US656944817 Oct 199727 May 2003Alza CorporationMethod for preventing crystal formation in a dispersion of a liquid in a matrix
US65728797 Jun 19953 Jun 2003Alza CorporationFormulations for transdermal delivery of pergolide
US659289229 Aug 200015 Jul 2003Tepha, Inc.Flushable disposable polymeric products
US661088712 Apr 200226 Aug 2003Sepracor Inc.Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US66491831 Nov 200118 Nov 2003Sepracor Inc.Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US666029529 Sep 19989 Dec 2003Alza CorporationTransdermal drug delivery device package with improved drug stability
US66643976 Mar 199816 Dec 2003Vernalis Research LimitedUse of (+)mefloquine for the treatment of malaria
US669949723 Jul 19992 Mar 2004Alza CorporationFormulations for the transdermal administration of fenoldopam
US670967619 Jun 200223 Mar 2004Schering CorporationExtended release oral dosage composition
US67100874 Jun 200223 Mar 2004Sepracor, Inc.Methods of treating or preventing neuropathic pain using sibutramine metabolites
US673421317 May 200211 May 2004Smithkline Beecham CorporationPharmaceutically active morpholinol
US6770295 *26 Aug 19993 Aug 2004Pharmacia AbTherapeutic formulation for administering tolterodine with controlled release
US682520524 Sep 200330 Nov 2004Euro-Celtique S.A.N-substituted hydromorphones and the use thereof
US685582017 May 200215 Feb 2005Smithkline Beecham CorporationPharmaceutically active morpholinol
US685858923 Jul 200222 Feb 2005Pharmacy And Therapeutic Advisory Consultancy Pty LtdMethods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US687871312 Dec 200212 Apr 2005Wockhardt LimitedGeneration triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US687874916 Jan 200312 Apr 2005Novartis AgMethod of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US689418920 Aug 200317 May 2005Sepracor Inc.Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US691147919 Aug 200228 Jun 2005Sepracor Inc.Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (−)-venlafaxine
US69518733 Mar 20004 Oct 2005Pfizer Inc.Methods for treating age-related behavioral disorders in companion animals
US696496623 Apr 200215 Nov 2005Wockhardt LimitedGeneration triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US697483723 Oct 200213 Dec 2005Sepracor Inc.Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
US697483823 Mar 200413 Dec 2005Sepracor Inc.Methods of treating or preventing pain using sibutramine metabolites
US697946319 Jun 200227 Dec 2005Schering CorporationStable extended release oral dosage composition
US699516829 May 20037 Feb 2006Euro-Celtique S.A.Triazaspiro compounds useful for treating or preventing pain
US699840017 May 200214 Feb 2006Smithkline Beecham CorporationPharmaceutically active morpholinol
US701184422 Nov 200214 Mar 2006Alza CorporationFormulations for the administration of fluoxetine
US701903017 Jul 200328 Mar 2006Celgene CorporationImmunotherapeutic agents
US703405928 Jun 200225 Apr 2006Sepracor Inc.Methods of using norfluoxetine
US706385918 Sep 200220 Jun 2006Noven Pharmaceuticals, Inc.Barrier film lined backing layer composition and method for topical administration of active agents
US707123425 Mar 20034 Jul 2006Sepracor Inc.Methods of treating or preventing erectile dysfunction
US707852630 May 200318 Jul 2006Transform Pharmaceuticals, Inc.CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US709442220 Aug 200322 Aug 2006Acrux Dds Pty Ltd.Topical delivery of antifungal agents
US709820617 May 200229 Aug 2006Smithkline Beecham CorporationPharmaceutically active morpholinol
US710533327 Mar 200212 Sep 2006Deadreon CorporationNucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US711243014 May 200226 Sep 2006Dendreon CorporationNucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US712570313 Mar 200224 Oct 2006Dendreon CorporationNucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US714169621 May 200428 Nov 2006Bridge Pharma, Inc.Smooth muscle spasmolytic agents
US716402331 Dec 200316 Jan 2007Wockhardt LimitedBenzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
US71694098 Sep 200330 Jan 2007Alza CorporationMethod for preventing crystal formation in a dispersion of a liquid in a matrix
US717289220 Mar 20026 Feb 2007Dendreon CorporationNucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US71762187 Jan 200513 Feb 2007Aryx TherapeuticsStereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US718295311 Dec 200027 Feb 2007Celgene CorporationMethods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US718686321 May 20046 Mar 2007Transform Pharmaceuticals, Inc.Sertraline compositions
US718974011 Apr 200313 Mar 2007Celgene CorporationMethods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US72054131 May 200317 Apr 2007Transform Pharmaceuticals, Inc.Solvates and polymorphs of ritonavir and methods of making and using the same
US721158223 Nov 19991 May 2007Sepracor Inc.Methods for treating urticaria using descarboethoxyloratadine
US721468316 Mar 19988 May 2007Sepracor Inc.Compositions of descarboethoxyloratadine
US721468417 Nov 20048 May 2007Sepracor Inc.Methods for the treatment of allergic rhinitis
US722964018 Dec 200112 Jun 2007Smithkline Beecham P.L.C.Paroxetine controlled release compositions
US72591524 Jun 200121 Aug 2007Alfa Wasserman, Inc.Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US727636420 Nov 20002 Oct 2007Dendreon CorporationNucleic acids encoding endotheliases, endotheliases and uses thereof
US728250923 Mar 200516 Oct 2007Aryx TherapeuticsStereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US729134718 Jan 20066 Nov 2007WyethSuccinate salt of O-desmethyl-venlafaxine
US73234796 Nov 200329 Jan 2008Celgene CorporationMethods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US732348024 May 200529 Jan 2008Metabolex, Inc.Substituted triazoles as modulators of PPAR and methods of their preparation
US732678731 Aug 20065 Feb 2008Aryx Therapeutics, Inc.Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
US732976116 Nov 200412 Feb 2008Celgene CorporationSubstituted imides
US735173929 Apr 20051 Apr 2008Wellgen, Inc.Bioactive compounds and methods of uses thereof
US73549486 Nov 20038 Apr 2008Celgene CorporationMethods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US73582467 Apr 200515 Apr 2008WyethThioamide derivatives as progesterone receptor modulators
US73938624 Oct 20051 Jul 2008Celgene CorporationMethod using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US739386316 Jan 20071 Jul 2008Celgene CorporationMethods of using N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide for the treatment and management of myelodysplastic syndromes
US739395720 Sep 20041 Jul 2008Wockhardt LimitedGeneration triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US740522316 Jan 200129 Jul 2008Schering CorporationTreating allergic and inflammatory conditions
US741406216 Jun 200519 Aug 2008Purdue Pharma L.P.Triazaspiro compounds useful for treating or preventing pain
US74389037 May 200421 Oct 2008Nbty, Inc.Methods and compositions that enhance bioavailability of coenzyme-Q10
US744610726 Aug 20044 Nov 2008Transform Pharmaceuticals, Inc.Crystalline forms of conazoles and methods of making and using the same
US74658003 Sep 200416 Dec 2008Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US74683638 Apr 200523 Dec 2008Celgene CorporationMethods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US747043517 Nov 200330 Dec 2008Andrx Pharmaceuticals, LlcExtended release venlafaxine formulation
US75110717 Mar 200831 Mar 2009WyethThioamide derivatives as progesterone receptor modulators
US751446625 Apr 20057 Apr 2009WyethPurification of progesterone receptor modulators
US751458330 May 20037 Apr 2009Proteotech, Inc.Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US751801731 Jan 200714 Apr 2009Idexx LaboratoriesFenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US755392326 Oct 200730 Jun 2009Metabolix, Inc.Medical devices and applications of polyhydroxyalkanoate polymers
US757281220 Jan 200611 Aug 2009Purdue Pharma, L.P., UsaTherapeutic agents useful for treating pain
US758263519 Dec 20031 Sep 2009Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US759233512 Apr 200622 Sep 2009Ranbaxy Laboratories LimitedOxazolidinone derivatives as antimicrobials
US761209623 Apr 20043 Nov 2009Celgene CorporationMethods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US76186493 Nov 200317 Nov 2009Schering CorporationExtended release oral dosage composition
US762213618 Jun 200424 Nov 2009Alza CorporationTransparent transdermal nicotine delivery devices
US762603224 Apr 20081 Dec 2009Wockhardt LimitedGeneration triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US762946625 Apr 20088 Dec 2009Aryx Therapeutics, Inc.Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
US764182529 Jul 20055 Jan 2010Tepha, Inc.Method of making a polyhydroxyalkanoate filament
US76422875 Aug 20055 Jan 2010Transform Pharmaceuticals, Inc.Statin pharmaceutical compositions and related methods of treatment
US765926512 Feb 20099 Feb 2010WyethThioamide derivatives as progesterone receptor modulators
US765928212 Jan 20059 Feb 2010Avanir Pharmaceuticals, Inc.Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US765928731 May 20079 Feb 2010Amgen Inc.Benzamide derivatives and uses related thereto
US767109327 May 20052 Mar 2010Transform Pharmaceuticals, Inc.Mixed co-crystals and pharmaceutical compositions comprising the same
US768306314 Jun 200423 Mar 2010Purdue Pharma L.P.Therapeutic agents useful for treating pain
US769620831 Jan 200613 Apr 2010Purdue Pharma L.P.Therapeutic agents useful for treating pain
US77003412 Feb 200120 Apr 2010Dendreon CorporationNucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US772802528 Dec 20041 Jun 2010Banyu Pharmaceutical Co., Ltd.2-heteroaryl-substituted benzimidazole derivative
US775472328 Jun 200613 Jul 2010Purdue Pharma, L.P., UsaTherapeutic agents useful for treating pain
US77674295 Mar 20043 Aug 2010Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US776769922 Dec 20053 Aug 2010Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US777220627 Feb 200910 Aug 2010Genzyme CorporationMethods and compositions for the treatment of autoimmune disorders using clofarabine
US777225421 Mar 200610 Aug 2010Purdue Pharma L.P.Therapeutic agents useful for treating pain
US777686123 Jan 200617 Aug 2010Purdue Pharma L.P.Therapeutic agents useful for treating pain
US777690730 Oct 200317 Aug 2010Celgene CorporationMethods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US779090529 Dec 20037 Sep 2010Mcneil-Ppc, Inc.Pharmaceutical propylene glycol solvate compositions
US779980720 Mar 200621 Sep 2010Purdue Pharma L.P.Therapeutic agents useful for treating pain
US779982029 Sep 200621 Sep 2010Banyu Pharmaceutical Co., Ltd.2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
US780336625 Aug 200828 Sep 2010Nbty, Inc.Methods and compositions that enhance bioavailability of coenzyme-Q10
US780378616 Jun 200528 Sep 2010Transform Pharmaceuticals, Inc.Pharmaceutical co-crystal compositions and related methods of use
US781216930 Nov 200112 Oct 2010The Children's Medical Center CorporationMethod of synthesis of 4-amino-thalidomide enantiomers
US78201996 Oct 200526 Oct 2010Schering CorporationStable extended release oral dosage composition
US78290814 Mar 20109 Nov 2010Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US784269113 Apr 200330 Nov 2010Celgene CorporationMethod for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US78464314 Mar 20107 Dec 2010Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US785521715 Dec 200821 Dec 2010Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US786329712 Nov 20074 Jan 2011Celgene CorporationMethods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes
US787160723 Feb 200518 Jan 2011Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US787984620 Sep 20071 Feb 2011Kyorin Pharmaceutical Co.., Ltd.Serine hydrolase inhibitors
US788348718 Dec 20088 Feb 2011Shantha Totada RTransdermal local anesthetic patch with injection port
US788809230 Oct 200915 Feb 2011Dendreon CorporationNucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US78927765 May 200822 Feb 2011The Regents Of The University Of CaliforniaScreening assay to identify modulators of protein kinase A
US78930455 Aug 200822 Feb 2011Celgene CorporationMethods for treating lymphomas in certain patient populations and screening patients for said therapy
US790220830 May 20088 Mar 2011Schering CorporationTreating allergic and inflammatory conditions
US792761311 Sep 200319 Apr 2011University Of South FloridaPharmaceutical co-crystal compositions
US79281326 Aug 200419 Apr 2011Ohio UniversityMethods for the amelioration of episodes of acute or chronic ulcerative colitis
US793191519 Nov 200826 Apr 2011Andrx Pharmaceuticals, LlcExtended release venlafaxine formulation
US793242112 Dec 200726 Apr 2011Amgen Inc.N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US794368331 Oct 200717 May 2011Tepha, Inc.Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US796460629 Jul 201021 Jun 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US796856915 May 200328 Jun 2011Celgene CorporationMethods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US797735723 Jul 200812 Jul 2011Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindo1-2-yl)-piperidine-2,6-dione
US799417721 Jul 20109 Aug 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US80083008 Jul 200930 Aug 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US801759816 May 200713 Sep 2011Knopp Neurosciences, Inc.Compositions of R(+) and S(−) pramipexole and methods of using the same
US802625410 Nov 200927 Sep 2011Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US80303102 Mar 20104 Oct 2011Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US803427030 Apr 200411 Oct 2011Tepha, Inc.Polyhydroxyalkanoate medical textiles and fibers
US805829224 May 201015 Nov 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US805844315 Dec 200815 Nov 2011Celgene CorporationProcesses for preparing polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-YL))-piperidine-2,6-dione
US806322113 Mar 200722 Nov 2011Kyorin Pharmaceutical Co., Ltd.Aminoquinolones as GSK-3 inhibitors
US807159110 Mar 20106 Dec 2011Kyorin Pharmaceutical Co., Ltd.7-cycloalkylaminoquinolones as GSK-3 inhibitors
US807591120 Aug 200713 Dec 2011Alza CorporationTransparent transdermal nicotine delivery devices
US808405915 Sep 200627 Dec 2011Alza CorporationAntidepressant dosage form
US808412511 Dec 200927 Dec 2011Tepha, Inc.Non-curling polyhydroxyalkanoate sutures
US810174515 Dec 200524 Jan 2012The Regents Of The University Of CaliforniaLung-targeted drugs
US810558615 Jun 201031 Jan 2012Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US811060215 Jul 20097 Feb 2012Purdue Pharma L.P.Compounds comprising heterocyclic-substituted piperidine for treating pain
US812938810 Jun 20116 Mar 2012Purde Pharma L.P.Therapeutic agents useful for treating pain
US813820416 Jul 200720 Mar 2012Aryx Therapeutics, Inc.Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US813836127 Dec 200620 Mar 2012The Trustees Of The University Of PennsylvaniaC-10 carbamates of taxanes
US814328615 Dec 200827 Mar 2012Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione)
US815316227 Sep 200610 Apr 2012Tissuetech, Inc.Purified amniotic membrane compositions and methods of use
US815380616 Jul 201010 Apr 2012The Children's Medical Center CorporationSynthesis of 4-amino-thalidomide enantiomers
US816395716 Jul 201024 Apr 2012Proteotech, Inc.Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
US816863520 Jun 20051 May 2012Human Biomolecular Research InstituteModulators of central nervous system neurotransmitters
US81686722 Feb 20101 May 2012WyethThioamide derivatives as progesterone receptor modulators
US817856017 Jun 201015 May 2012Purdue Pharma L.P.Therapeutic agents useful for treating pain
US818284027 Sep 200622 May 2012Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US818284127 Sep 200622 May 2012Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and anti-inflammation methods
US818329020 Jul 201022 May 2012Mcneil-Ppc, Inc.Pharmaceutically acceptable propylene glycol solvate of naproxen
US818338110 Jul 200822 May 2012Metabolex Inc.N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US81876302 Oct 200929 May 2012Schering-Plough CorporationExtended release oral dosage composition
US818763927 Sep 200629 May 2012Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US818811819 Feb 200929 May 2012Celgene CorporationMethod for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies
US81932193 Oct 20115 Jun 2012Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US819826219 Aug 200812 Jun 2012Celgene CorporationMethods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US819830617 Dec 200912 Jun 2012Celgene CorporationMethods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a proteasome inhibitor
US820251720 Feb 200919 Jun 2012Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US82029996 Jan 200619 Jun 2012Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US82072008 May 200826 Jun 2012Celgene CorporationMethods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione follow by autologous stem cell transplantation
US82114285 Jul 20073 Jul 2012Torrey Pines Institute For Molecular StudiesProtease screening methods and proteases identified thereby
US821916813 Apr 200410 Jul 2012Abbott Diabetes Care Inc.Article and method for applying a coupling agent for a non-invasive optical probe
US822225730 Mar 200617 Jul 2012The Regents Of The University Of CaliforniaPhosphono-pent-2-en-1-yl nucleosides and analogs
US822746716 Feb 201024 Jul 2012Purdue Pharma L.P.Therapeutic agents useful for treating pain
US82274848 Mar 201224 Jul 2012Avanir Pharmaceuticals, Inc.Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US82362886 Jan 20127 Aug 2012Skinmedica, Inc.Melanin modification compositions and methods of use
US824166221 Dec 200614 Aug 2012Watson Laboratories, Inc.Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
US824742311 Jul 200821 Aug 2012Tragara Pharmaceuticals, Inc.Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US825769915 Dec 20114 Sep 2012Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US826363716 May 200311 Sep 2012Celgene CorporationMethods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide
US826904025 Nov 200318 Sep 2012Wyeth LlcDerivatives of venlafaxine and methods of preparing and using the same
US827336126 Sep 200725 Sep 2012Infectious Disease Research InstituteVaccine composition containing synthetic adjuvant
US828838416 Nov 200916 Oct 2012Metabolex, Inc.Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US829911716 Jun 201030 Oct 2012Metabolex Inc.GPR120 receptor agonists and uses thereof
US830441828 May 20086 Nov 2012Agennix AgPyrazolopyrimidinone kinase inhibitor
US830959412 Feb 200913 Nov 2012Wyeth LlcPurification of progesterone receptor modulators
US830960017 Dec 200913 Nov 2012Metabolex Inc.GPR120 receptor agonists and uses thereof
US83141301 Oct 200920 Nov 2012Synta Pharmaceuticals Corp.Compounds inclunding substituted pyridines for inflammation and immune-related uses
US83141345 Mar 201020 Nov 2012Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US831870018 Jan 201227 Nov 2012The Regents Of The University Of CaliforniaLung-targeted drugs
US834351220 Oct 20111 Jan 2013Infectious Disease Research InstituteTreatment of allergic conditions using a composition containing synthetic adjuvant
US834984220 Jul 20098 Jan 2013Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US834985126 Feb 20108 Jan 2013Ambit Biosciences Corp.JAK kinase modulating compounds and methods of use thereof
US836127227 Jun 200729 Jan 2013Ferring B.V.Polyurethane elastomers
US83612736 Sep 201229 Jan 2013Ferring B.V.Polyurethane elastomers
US836206224 Dec 200329 Jan 2013Mcneil-Ppc, Inc.Pharmaceutical compositions with improved dissolution
US83779795 Dec 200619 Feb 2013Taro Pharmaceuticals North America, Inc.Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
US838314922 Sep 200626 Feb 2013Alza CorporationHigh enhancer-loading polyacrylate formulation for transdermal applications
US838951411 Sep 20085 Mar 2013Kyorin Pharmaceutical Co., Ltd.Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
US838954925 Apr 20085 Mar 2013Purdue Pharma L.P.Substituted pyridines useful for treating pain
US839480720 Nov 200912 Mar 2013Purdue Research FoundationQuinazoline inhibitors of BACE 1 and methods of using
US840471611 May 201026 Mar 2013Celgene CorporationMethods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US840471724 Mar 201126 Mar 2013Celgene CorporationMethods of treating myelodysplastic syndromes using lenalidomide
US840472829 Jul 201026 Mar 2013Mayo Foundation For Medical Education And ResearchSmall-molecule botulinum toxin inhibitors
US841012720 Sep 20102 Apr 2013Metabolex, Inc.Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US84101367 Apr 20102 Apr 2013Celgene CorporationMethods for treatment of hepatocellular carcinoma using 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
US84152945 Jun 20089 Apr 2013Arizona Board Of RegentsCyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
US8419793 *12 Mar 201016 Apr 2013Mentor Worldwide LlcCoating with antimicrobial agents
US842012623 Apr 201216 Apr 2013Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8420153 *19 Sep 200816 Apr 2013Mentor Worldwide LlcCoating with antimicrobial agents
US843112416 Apr 200930 Apr 2013Halozyme, Inc.Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
US843138020 Feb 200930 Apr 2013Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US843159826 May 201130 Apr 2013Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US844019419 Feb 200814 May 2013Celgene CorporationMethods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US844023523 Apr 201214 May 2013Tissuetech, Inc.Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US844070516 Sep 200514 May 2013Whitehead Institute For Biomedical ResearchCompounds, compositions and methods of inhibiting alpha-synuclein toxicity
US84454745 Aug 201121 May 2013Knopp Neurosciences, Inc.Compositions of R(+) and S(−) pramipexole and methods of using the same
US84504703 Jun 200928 May 2013Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US845500923 Apr 20124 Jun 2013Tissuetech, Inc.Amniotic membrane preparations and purified compositions and anti-inflammation methods
US845565825 Jan 20074 Jun 2013Synta Pharmaceuticals Corp.Thiazole and thiadiazole compounds for inflammation and immune-related uses
US846070726 Mar 201211 Jun 2013Ferring B.V.Stabilised prostaglandin composition
US84607143 Apr 201211 Jun 2013Tissuetech, Inc.Purified amniotic membrane compositions and methods of use
US847081726 Oct 201025 Jun 2013Sunesis Pharmaceuticals, Inc.Compounds and methods for treatment of cancer
US847626112 Sep 20082 Jul 2013Kyorin Pharmaceutical Co., Ltd.Spirocyclic aminoquinolones as GSK-3 inhibitors
US847627120 Jan 20112 Jul 2013Purdue Pharma, L.P.Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US847627725 Apr 20082 Jul 2013Purdue Pharma L.P.TRPV1 antagonists including dihydroxy substituent and uses thereof
US84763084 Oct 20122 Jul 2013Metabolex, Inc.GPR120 receptor agonists and uses thereof
US848150131 May 20059 Jul 2013Human Biomolecular Research InstituteSynthesis of metabolically stable analgesics, pain medications and other agents
US84866684 Aug 201116 Jul 2013Ritter Pharmaceuticals, Inc.Prebiotic formulations and methods of use
US849193428 Jul 200523 Jul 2013Ferring B.V.Stabilised prostaglandin composition
US849212417 Feb 201023 Jul 2013Ritter Pharmaceuticals, Inc.Prebiotic formulations and methods of use
US84924067 Apr 201023 Jul 2013Celgene CorporationMethods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
US84924233 Apr 201223 Jul 2013Mcneil-Ppc, Inc.Pharmaceutical propylene glycol solvate compositions
US849242820 Sep 200623 Jul 2013Mayo Foundation For Medical Education And ResearchSmall-molecule botulinum toxin inhibitors
US851892614 Dec 200727 Aug 2013Knopp Neurosciences, Inc.Compositions and methods of using (R)-pramipexole
US851895025 Jan 200627 Aug 2013Synta Pharmaceuticals Corp.2-amido pyrazines for inflammation and immune related uses
US851895816 Oct 200727 Aug 2013Forma Therapeutics, Inc.Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
US851914814 Mar 200827 Aug 2013Knopp Neurosciences, Inc.Synthesis of chirally purified substituted benzothiazole diamines
US852425415 Oct 20073 Sep 2013Ferring B.V.Bioresorbable polymers
US852469514 Mar 20083 Sep 2013Knopp Neurosciences, Inc.Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US852473610 Feb 20123 Sep 2013Armetheon, Inc.Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US852475616 Oct 20123 Sep 2013Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US85304988 Apr 201310 Sep 2013Celgene CorporationMethods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
US85361778 Aug 201117 Sep 2013Purdue Pharma L.P.Therapeutic agents useful for treating pain
US854638822 Oct 20091 Oct 2013Purdue Pharma L.P.Heterocyclic TRPV1 receptor ligands
US855728113 Jul 201015 Oct 2013Ferring B.V.Water-swellable polymers
US85802526 Jul 201212 Nov 2013Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US858672615 Jan 201019 Nov 2013The Trustees Of Columbia University In The City Of New YorkTissue-specific MicroRNAs and compositions and uses thereof
US859244522 Jun 201226 Nov 2013Map Pharmaceuticals, Inc.Iso-ergoline derivatives
US859248614 May 201226 Nov 2013Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US85983745 Oct 20123 Dec 2013Metabolex, Inc.GPR120 receptor agonists and uses thereof
US860403522 Jun 201210 Dec 2013Map Pharmaceuticals, Inc.Fluoroergoline analogs
US860403718 Aug 201110 Dec 2013Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US860911430 Aug 201217 Dec 2013Infectious Diesease Research InstituteMethods of using a vaccine composition containing synthetic adjuvant
US860971214 Sep 201217 Dec 2013Wyeth LlcPurification of progesterone receptor modulators
US861828917 Mar 200931 Dec 2013Ambit Biosciences CorporationRAF kinase modulator compounds and methods of use thereof
US86233848 May 20137 Jan 2014Celgene CorporationMethods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia
US862879810 Aug 201214 Jan 2014Ferring B.V.Water-swellable polymers
US86327872 Dec 201121 Jan 2014Celgene CorporationMethods using immunomodulatory compounds for treatment of certain leukemias
US863280012 May 200621 Jan 2014Alza CorporationMultilayer drug delivery system with barrier against reservoir material flow
US863320731 Aug 201121 Jan 2014Ambit Biosciences CorporationQuinazoline compounds and methods of use thereof
US863708723 Nov 200928 Jan 2014Jb Therapeutics Inc.Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids
US863750212 Jan 201228 Jan 2014Purde Pharma L.P.2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain
US863754821 Sep 201028 Jan 2014Purdue Pharma L.P.Therapeutic agents useful for treating pain
US864266225 May 20124 Feb 2014Sunovion Pharmaceuticals Inc.Methods of using derivatives of (−)-venlafaxine
US86480955 Jun 201211 Feb 2014Celgene CorporationMethods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor
US86530669 Oct 200718 Feb 2014Charleston Laboratories, Inc.Pharmaceutical compositions
US20060200100 *16 Feb 20067 Sep 2006Rosati Coni FMethod and apparatus for supplying gas to an area
US20100121304 *10 Nov 200813 May 2010Kimberly-Clark Worldwide, Inc.Multifunctional Acrylate Skin-Adhesive Composition
US20130018335 *13 Jan 201117 Jan 2013Laboratoires UrgoNovel bandage including agglomerates of particles suitable for rapidly gelling or solubilising
USRE32991 *25 Jul 198818 Jul 1989Thermedics, Inc.Drug dispensing wound dressing
USRE379343 Feb 200010 Dec 2002Lts Lohmann Therapie-Systeme AgTransdermal therapeutic system
USRE3958831 Oct 199024 Apr 2007Alza CorporationTransdermal drug delivery device
USRE4212630 Jun 20008 Feb 2011The Procter & Gamble CompanyDelivery system for oral care compositions comprising organosiloxane resins using a removable backing strip
DE2642032A1 *18 Sep 197630 Mar 1978Merck Patent GmbhSiliciumdioxidhaltige zubereitungen und verfahren zu ihrer herstellung
DE3500508A1 *9 Jan 198512 Sep 1985Nitto Electric Ind CoPraeparat zur perkutanen verabreichung von arzneimitteln und verfahren zu dessen herstellung
DE102010053792A18 Dec 201014 Jun 2012Frank BecherDevice for germ-free keeping of surfaces, such as door handles, handrails, grip bars, handles of shopping carts and toilet seating surfaces, has flat support material and self-adhesive portion formed on one side of flat support material
DE102013202928A122 Feb 201329 Aug 2013Golden Biotechnology CorporationVerfahren und Zusammensetzungen zum Behandeln von Krebsmetastasierung
EP0011471A1 *12 Nov 197928 May 1980SMITH & NEPHEW RESEARCH LIMITEDAdhesive-coated sheet material incorporating anti-bacterial substances
EP0013606A2 *4 Jan 198023 Jul 1980Key Pharmaceuticals, Inc.Drug delivery device and method for its preparation
EP0020905A1 *15 Apr 19807 Jan 1981C.H. Boehringer SohnPharmaceutical composition in the form of a polyacrylate film, and its preparation
EP0023395A1 *2 Jul 19804 Feb 1981Minnesota Mining And Manufacturing CompanyPressure-sensitive adhesive having a broad spectrum anti-microbial therein
EP0040861A1 *4 Jan 19802 Dec 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix and method of its preparation
EP0040862A1 *4 Jan 19802 Dec 1981Key Pharmaceuticals, Inc.Burn matrix, method of its preparation and delivery device comprising said matrix
EP0055023A2 *16 Nov 198130 Jun 1982E.R. Squibb & Sons, Inc.Antiseptic containing adhesive composition
EP0184910A2 *15 Nov 198518 Jun 1986Hercon Laboratories CorporationDevice for controlled release drug delivery
EP0206741A217 Jun 198630 Dec 1986Merck Frosst Canada Inc.Leukotriene antagonists
EP0239306A218 Mar 198730 Sep 1987Merck Frosst Canada Inc.Tetrahydrocarbazole esters
EP0273004A2 *16 Nov 198729 Jun 1988Ciba-Geigy AgUser-activated therapeutical system
EP0279977A2 *28 Sep 198731 Aug 1988Alza CorporationTransdermal administration of progesterone, estradiol esters and mixtures thereof
EP0328524A1 *28 Aug 198723 Aug 1989Univ RutgersTransdermal fertility control system and process.
EP0399765A2 *21 May 199028 Nov 1990Advanced Polymer Systems, Inc.System for transdermal drug delivery
EP0480716A110 Oct 199115 Apr 1992Merck Frosst Canada Inc.Saturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0484543A1 *23 Apr 199113 May 1992Teijin LimitedPlaster
EP1602369A223 Aug 20007 Dec 2005Sepracor, Inc.Bupropion Metabolites and Methods of their Synthesis and Use
EP1674068A119 Feb 199728 Jun 2006Acrux DDS Pty LtdDermal penetration enhancers and drug delivery systems involving same
EP1712232A111 Dec 199518 Oct 2006Sepracor, Inc.Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
EP1759701A229 Feb 20007 Mar 2007Sepracor, Inc.Buproprion Metabolites and Methods of Their Synthesis and Use.
EP1867644A123 Jul 200419 Dec 2007Euro-Celtique S.A.Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
EP1889614A225 Aug 200020 Feb 2008APBI Holdings, LLCMethods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
EP1900369A113 Apr 200319 Mar 2008Celgene CorporationMethods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
EP1967189A118 Feb 200510 Sep 2008GPC Biotech AGMethods for treating resistant or refractory tumors
EP1980252A217 Jul 200315 Oct 2008Avanir PharmaceuticalsPharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP2002827A231 Oct 200217 Dec 2008The Baylor College Of MedicineMethods and compositions for control of bone formation via modulation of sympathetic tone
EP2011507A215 Sep 20007 Jan 2009Novartis AGPharmaceutical composition of nateglinide and another antidiabetic agent
EP2016942A113 Dec 200021 Jan 2009Celgene CorporationMethods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
EP2017276A121 Sep 200421 Jan 2009Euro-Celtique S.A.Phenyl-carboxamide compounds useful for treating pain
EP2030620A18 May 20004 Mar 2009Wockhardt Limited(s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
EP2033951A231 Jan 200311 Mar 2009Euro-Celtique S.A.2-Piperazine-pyridines useful for treating pain
EP2036553A124 Oct 200318 Mar 2009Celgene CorporationMethods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP2065383A119 Nov 20043 Jun 2009Signal Pharmaceuticals, Inc.Indazole compounds and methods of use thereof as protein kinase inhibitors
EP2067776A123 Jul 200410 Jun 2009Euro-Celtique S.A.Piperidine compounds and pharmaceutical compositions containing them
EP2074995A120 Mar 20031 Jul 2009Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP2077112A14 Nov 20048 Jul 2009Celgene CorporationMethods and compositions using thalidomide for the treatment and management of cancers and idiopathic pulmonary fibrosis
EP2087891A216 May 200312 Aug 2009Celgene CorporationPharmaceutical compositions for treating lymphoma
EP2096107A123 Dec 20042 Sep 2009GPC Biotech AGDerivatives of squaric acid with anti-proliferative activity
EP2105135A216 May 200330 Sep 2009Celgene CorporationPharmaceutical compositions for treating cancer
EP2105136A216 May 200330 Sep 2009Celgene CorporationPharmaceutical compositions for treating cancer
EP2112150A122 Apr 200828 Oct 2009GPC Biotech AGImproved raf inhibitors
EP2112152A122 Apr 200828 Oct 2009GPC Biotech AGDihydropteridinones as Plk Inhibitors
EP2133325A131 Mar 200016 Dec 2009Sepracor Inc.Derivatives of venlafaxine and methods of preparing and using the same
EP2158903A214 Dec 19993 Mar 2010ALZA CorporationTransparent Transdermal Nicotine Delivery Devices
EP2163643A15 Mar 200417 Mar 2010Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2177620A15 Mar 200421 Apr 2010Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2194053A17 Jan 20059 Jun 2010Aryx Therapeutics, Inc.Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP2201840A128 Dec 200630 Jun 2010Pharmacyclics, Inc.Inhibitors of Bruton's Tyrosine Kinase
EP2218779A115 Dec 200318 Aug 2010Halozyme, Inc.Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2223687A120 Mar 20031 Sep 2010Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
EP2223688A120 Mar 20031 Sep 2010Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
EP2258363A116 May 20038 Dec 2010Celgene CorporationCompositions for treatment of cancers
EP2272512A116 May 200312 Jan 2011Celgene CorporationPharmaceutical compositions for treating cancer
EP2272513A116 May 200312 Jan 2011Celgene CorporationPharmaceutical compositions for treating cancer
EP2280008A215 Jan 20082 Feb 2011Purdue Pharma L.P.Heterocyclic-substituted piperidines as ORL-1 ligands
EP2289497A19 Nov 20062 Mar 2011Circ Pharma Research and Development LimitedOnce-daily administration of central nervous system drugs
EP2292213A11 Feb 20059 Mar 2011Cephalon, Inc.Compositions comprising a polymorphic form of armodafinil
EP2295416A217 Nov 200516 Mar 2011Synta Pharmaceuticals Corp.Triazole compounds that modulate HSP90 activity
EP2298748A217 Nov 200523 Mar 2011Synta Pharmaceuticals Corp.Triazole compounds that modulate HSP90 activity
EP2298764A121 Nov 200623 Mar 2011Purdue Pharma LP4-Oxadiazolyl-piperidine compounds and use thereof
EP2298765A121 Nov 200623 Mar 2011Purdue Pharma LP4-Oxadiazolyl-piperidine compounds and use thereof
EP2298770A12 Nov 200623 Mar 2011ChemBridge CorporationHeterocyclic compounds as TrkA modulators
EP2298874A115 Dec 200323 Mar 2011Halozyme, Inc.Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2308480A222 Sep 200613 Apr 2011ALZA CorporationHigh Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
EP2311973A15 Mar 200420 Apr 2011Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2316437A112 May 20064 May 2011Alza CorporationMultilayer drug delivery system with barrier against reservoir material flow
EP2316455A116 May 20034 May 2011Celgene CorporationPharmaceutical compositions for treating cancer
EP2319516A122 Jul 200411 May 2011Synta Pharmaceuticals Corp.Compounds for treating inflammatory and autoimmune disorders
EP2322179A117 Jul 200318 May 2011Avanir Pharmaceuticals, Inc.Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders
EP2325185A128 Oct 200925 May 2011GPC Biotech AGPlk inhibitor
EP2330213A15 Mar 20048 Jun 2011Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2339328A224 Dec 200329 Jun 2011Transform Pharmaceuticals, Inc.Pharmaceutical co-crystal compositions of celecoxib
EP2380564A24 Apr 200826 Oct 2011Sigmoid Pharma LimitedAn oral pharmaceutical composition
EP2383271A113 Mar 20072 Nov 2011Kyorin Pharmaceutical Co., Ltd.Aminoquinolones as GSK-3 Inhibitors
EP2399578A111 May 200628 Dec 2011The Interthyr CorporationMethods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
EP2405015A25 Mar 200411 Jan 2012Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2409691A14 Apr 200825 Jan 2012Sigmoid Pharma LimitedPharmaceutical cyclosporin compositions
EP2420490A120 Mar 200322 Feb 2012Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
EP2420497A125 Sep 200722 Feb 2012Celgene Corporation5-substituted quinazolinone derivatives as anti-cancer agents
EP2420498A125 Sep 200722 Feb 2012Celgene Corporation5-substituted quinazolinone derivatives as anti-cancer agents
EP2428513A125 Sep 200714 Mar 2012Celgene Corporation5-substituted quinazolinone derivatives as anti-cancer agents
EP2433634A216 Sep 200528 Mar 2012The Whitehead Institute for Biomedical ResearchCompounds, compositions and methods of inhibiting a-synuclein toxicity
EP2433935A129 Aug 200828 Mar 2012Purdue Pharma LPSubstituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433936A129 Aug 200828 Mar 2012Purdue Pharma LPSubstituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433937A129 Aug 200828 Mar 2012Purdue Pharma LPSubstituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2443929A128 Dec 200625 Apr 2012Pharmacyclics, Inc.Inhibitors of Bruton's Tyrosine Kinase
EP2460522A25 May 20046 Jun 2012Celgene CorporationMethods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP2471518A218 May 20104 Jul 2012Sigmoid Pharma LimitedComposition comprising oil drops
EP2476690A11 Jul 200918 Jul 2012IDENIX Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
EP2479173A125 Apr 200825 Jul 2012Purdue Pharma LPTherapeutic agents useful for treating pain
EP2500337A221 Feb 200819 Sep 2012Sepracor Inc.Solid form comprising (-) o-desmethylvenlafaxine and uses thereof
EP2502921A121 Apr 201026 Sep 2012Axikin Pharmaceuticals, Inc.Arylsulfonamide CCR3 antagonists
EP2505200A118 Mar 20053 Oct 2012Celgene CorporationMethods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
EP2514740A113 Mar 200824 Oct 2012Auspex Pharmaceuticals, Inc.Deuterated O-desmethylvenlafaxines with serotoninergic and/or norepinephrinergic activity
EP2514745A117 Dec 200924 Oct 2012Metabolex Inc.GPR120 receptor agonists and uses thereof
EP2520561A19 Jun 20087 Nov 2012MannKind CorporationIRE-1A Inhibitors
EP2526771A128 Dec 200628 Nov 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2526933A228 Dec 200628 Nov 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2526934A228 Dec 200628 Nov 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2526946A13 Oct 200628 Nov 2012Celgene CorporationMethods Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione For Treatment Of Certain Leukemias
EP2527315A130 May 200328 Nov 2012Proteotech Inc.Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
EP2529621A128 Dec 20065 Dec 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2529622A128 Dec 20065 Dec 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2530083A128 Dec 20065 Dec 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2532234A128 Dec 200612 Dec 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2532235A128 Dec 200612 Dec 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2532643A19 Jun 200812 Dec 2012MannKind CorporationIRE-1A Inhibitors
EP2537844A120 Jul 200926 Dec 2012Purdue Pharma L.P.Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EP2561872A116 Dec 200527 Feb 2013Anadys Pharmaceuticals, Inc.3, 5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof
EP2561874A216 May 200327 Feb 2013Celgene CorporationPharmaceutical compositions for treating cancer
EP2572712A22 Jun 200827 Mar 2013The Trustees Of Princeton UniversityTreatment of viral infections by modulation of host cell metabolic pathways
EP2586428A125 Apr 20081 May 2013Sigmoid Pharma LimitedManufacture of multiple minicapsules
EP2604598A125 Apr 200819 Jun 2013Purdue Pharma L.P.TRPV1 antagonists and uses thereof
EP2604599A125 Apr 200819 Jun 2013Purdue Pharma LPTRPV1 antagonists and uses thereof
EP2617423A119 Oct 200724 Jul 2013Genzyme CorporationPurine derivatives for the treatment of cystic diseases
EP2617704A12 Jun 200824 Jul 2013Sepracor Inc.Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2650294A112 Oct 201016 Oct 2013Pharmacyclics, Inc.Inhibitors of Bruton's Tyrosine Kinase
EP2662090A114 Apr 200913 Nov 2013Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2664337A127 Sep 200620 Nov 2013TissueTech, Inc.Amniotic membrane preparations and purified compositions and methods of use
EP2687213A127 Mar 200822 Jan 2014Celgene CorporationSolid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2690095A120 Oct 200929 Jan 2014Camabay Therapeutics, Inc.Aryl gpr120 receptor agonists and uses thereof
EP2695616A127 Mar 200812 Feb 2014Celgene CorporationSolid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2703404A130 Jul 20095 Mar 2014Purdue Pharma L.P.Buprenorphine analogs
WO1980001041A1 *15 Nov 197929 May 1980D SeymourAdhesive-coated sheet material incorporating anti-bacterial substances
WO1987000042A1 *27 Jun 198615 Jan 1987Univ New JerseyTransdermal verapamil delivery device
WO1987001938A1 *11 Sep 19869 Apr 1987Univ CaliforniaLiposome transdermal drug delivery system
WO1987007138A1 *29 May 19873 Dec 1987Univ RutgersTransdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
WO1998055043A127 Apr 199810 Dec 1998Gillette CanadaDental hygiene article
WO2003022259A112 Sep 200220 Mar 2003Sepracor IncMethods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
WO2003077847A27 Mar 200325 Sep 2003Helen M ArmstrongSubstituted amides
WO2003101927A130 May 200311 Dec 2003Proteotech IncCompounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2004009558A223 Jul 200329 Jan 2004Ptc Therapeutics IncUreido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2004078161A14 Sep 200316 Sep 2004Transform Pharmaceuticals IncPharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004081001A113 Feb 200423 Sep 2004Banyu Pharma Co LtdNovel 2-pyridinecarboxamide derivatives
WO2005009539A222 Jul 20043 Feb 2005Shoujun ChenCompounds for inflammation and immune-related uses
WO2005066126A113 Dec 200421 Jul 2005Lilly Co EliCb1 modulator compounds
WO2005089767A110 Mar 200529 Sep 2005Barton Aron KamenUse of aminopterin for treating cancer and inflammatory disorders
WO2005099569A1 *7 Apr 200527 Oct 2005Abbott LabArticle and method for applying a coupling agent for a non-invasive optical probe
WO2006049304A11 Nov 200511 May 2006Banyu Pharma Co LtdAryloxy-substituted benzimidazole derivatives
WO2006066074A215 Dec 200522 Jun 2006Univ CaliforniaLung-targeted drugs
WO2006119365A22 May 20069 Nov 2006Cold Spring Harbor LabComposition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2007013929A120 Jul 20061 Feb 2007Amgen IncAniline sulfonamide derivatives and their uses
WO2007027527A225 Aug 20068 Mar 2007Celgene CorpIsoindole-imide compounds and compositions comprising and methods of using the same
WO2007028073A231 Aug 20068 Mar 2007Aryx TherapeuticsSynthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007035939A222 Sep 200629 Mar 2007Alza CorpHigh enhancer-loading polyacrylate formulation for transdermal applications
WO2007037534A129 Sep 20065 Apr 2007Banyu Pharma Co Ltd2-heteroaryl-substituted indole derivative
WO2007062266A228 Nov 200631 May 2007Marinus PharmaceuticalsGanaxolone formulations and methods for the making and use thereof
WO2007087442A225 Jan 20072 Aug 2007Synta Pharmaceuticals CorpSubstituted biaryl compounds for inflammation and immune-related uses
WO2007087443A225 Jan 20072 Aug 2007Synta Pharmaceuticals CorpVinyl-phenyl derivatives for inflammation and immune-related uses
WO2007150002A221 Jun 200727 Dec 2007Anadys Pharmaceuticals IncPRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE
WO2008011406A217 Jul 200724 Jan 2008Anadys Pharmaceuticals IncCarbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2008019065A12 Aug 200714 Feb 2008Celgene CorpUse of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
WO2008021368A213 Aug 200721 Feb 2008Norman HaugheyCompositions and methods for neuroprotection
WO2008027542A229 Aug 20076 Mar 2008Celgene Corp5-substituted isoindoline compounds
WO2008039489A225 Sep 20073 Apr 2008Celgene Corp5-substituted quinazolinone derivatives as antitumor agents
WO2008039520A226 Sep 20073 Apr 2008Qinglin CheFused ring compounds for inflammation and immune-related uses
WO2008044777A15 Oct 200717 Apr 2008Masanori Asai2-pyridinecarboxamide derivative having gk-activating activity
WO2008066131A129 Nov 20075 Jun 2008Banyu Pharma Co LtdNovel phenyl-isoxazol-3-ol derivative
WO2008066899A228 Nov 20075 Jun 2008Marinus PharmaceuticalsNanoparticulate formulations and methods for the making and use thereof
WO2008094476A125 Jan 20087 Aug 2008Merck & Co IncSubstituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators
WO2008106166A227 Feb 20084 Sep 2008Conatus Pharmaceuticals IncMethods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
WO2008122965A24 Apr 200816 Oct 2008Sigmoid Pharma LtdPharmaceutical cyclosporin compositions
WO2008122967A24 Apr 200816 Oct 2008Sigmoid Pharma LtdAn oral pharmaceutical composition
WO2009017818A131 Jul 20085 Feb 2009Synta Pharmaceuticals CorpHeterocycle-aryl compounds for inflammation and immune-related uses
WO2009017831A131 Jul 20085 Feb 2009Synta Pharmaceuticals CorpVinyl-aryl derivatives for inflammation and immune-related uses
WO2009042177A125 Sep 20082 Apr 2009Celgene Corp6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2009063821A110 Nov 200822 May 2009Banyu Pharma Co LtdHeteroaryloxy quinazoline derivative
WO2009081782A115 Dec 20082 Jul 2009Banyu Pharma Co LtdN-pyrazole-2-pyridinecarboxamide derivative
WO2009147990A128 May 200910 Dec 2009Banyu Pharmaceutical Co.,Ltd.Novel isoxazole derivative
WO2010014229A130 Jul 20094 Feb 2010Purdue Pharma L.P.Buprenorphine analogs
WO2010027975A11 Sep 200911 Mar 2010Anacor Pharmaceuticals, Inc.Boron-containing small molecules
WO2010039308A126 Jun 20098 Apr 2010Proteotech Inc.COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF β-AMYLOID DISEASES AND SYNUCLEINOPATHIES
WO2010042834A19 Oct 200915 Apr 2010Anadys Pharmaceuticals, Inc.A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
WO2010071866A219 Dec 200924 Jun 2010Nuon Therapeutics, Inc.Combination therapy for arthritis with tranilast
WO2010075064A115 Dec 20091 Jul 2010Sepracor Inc.Triple reuptake inhibitors and methods of their use
WO2010075255A221 Dec 20091 Jul 2010Sloan-Kettering Institute For Cancer ResearchMethods for treating or preventing cancer and neurodegenerative diseases
WO2010075280A221 Dec 20091 Jul 2010Sloan-Kettering Institute For Cancer ResearchCoumarin-based compounds
WO2010076329A130 Dec 20098 Jul 2010Scynexis, Inc.Derivatives of cyclosporin a
WO2010077297A19 Dec 20098 Jul 2010Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
WO2010088450A229 Jan 20105 Aug 2010Celladon CorporationMethods for treating diseases associated with the modulation of serca
WO2010093425A111 Feb 201019 Aug 2010Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2010093434A19 Feb 201019 Aug 2010Celgene CorporationIsotopologues of lenalidomide
WO2010093588A19 Feb 201019 Aug 2010Celgene CorporationMethods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
WO2010095767A122 Feb 201026 Aug 2010Banyu Pharmaceutical Co.,Ltd.Pyrimidin-4(3h)-one derivatives
WO2010099379A126 Feb 20102 Sep 2010Ambit Biosciences CorporationJak kinase modulating quinazoline derivatives and methods of use thereof
WO2010101967A23 Mar 201010 Sep 2010Idenix Pharmaceuticals, Inc.Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2010102262A15 Mar 201010 Sep 2010Halozyme, Inc.Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
WO2010104195A19 Mar 201016 Sep 2010Banyu Pharmaceutical Co.,Ltd.Novel isoindolin-1-one derivative
WO2010105016A111 Mar 201016 Sep 2010Ambit Biosciences Corp.Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
WO2010110685A226 Mar 201030 Sep 2010Pathway Therapeutics LimitedPyrimddinyl and 1,3,5-triazinyl benzimtoazole sulfonamides and their use in cancer therapy
WO2010110686A126 Mar 201030 Sep 2010Pathway Therapeutics LimitedPyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
WO2010127452A14 May 201011 Nov 2010The Royal Institution For The Advancement Of Learning/Mcgill University5-oxo-ete receptor antagonist compounds
WO2010144571A19 Jun 201016 Dec 2010Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011003870A25 Jul 201013 Jan 2011Creabilis S.A.Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
WO2011005119A16 Jul 201013 Jan 2011Pathway Therapeutics LimitedPyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011009961A126 Jul 201027 Jan 2011Virologik GmbhCombination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011014775A130 Jul 20103 Feb 2011The Brigham And Women's Hospital, Inc.Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
WO2011017389A14 Aug 201010 Feb 2011Idenix Pharmaceuticals, Inc.Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011018504A212 Aug 201017 Feb 2011Sigmoid Pharma LimitedImmunomodulatory compositions comprising a polymer matrix and an oil phase
WO2011022473A118 Aug 201024 Feb 2011Ambit Biosciences CorporationBiaryl compounds and methods of use thereof
WO2011031816A29 Sep 201017 Mar 2011Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011031818A29 Sep 201017 Mar 2011Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011041154A120 Sep 20107 Apr 2011Metabolex, Inc.Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011042482A16 Oct 201014 Apr 2011Green MolecularPolyphenols for use in the treatment of cancer
WO2011049946A119 Oct 201028 Apr 2011Synta Pharmaceuticals Corp.Combination cancer therapy with hsp90 inhibitory compounds
WO2011056566A226 Oct 201012 May 2011Sunesis Pharmaceuticals, Inc.Compounds and methods for treatment of cancer
WO2011056764A12 Nov 201012 May 2011Ambit Biosciences Corp.Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011063076A118 Nov 201026 May 2011Itherx Pharmaceuticals, Inc.Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011063102A118 Nov 201026 May 2011Celgene CorporationApremilast for the treatment of sarcoidosis
WO2011064769A122 Nov 20103 Jun 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069002A12 Dec 20109 Jun 2011Alquest Therapeutics, Inc.Organoselenium compounds and uses thereof
WO2011070364A19 Dec 201016 Jun 2011Scynexis, Inc.Novel cyclic peptides
WO2011075615A117 Dec 201023 Jun 2011Idenix Pharmaceuticals, Inc.5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011079091A121 Dec 201030 Jun 2011Celgene Corporation(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
WO2011082289A130 Dec 20107 Jul 2011Scynexis Inc.Cyclosporine analogues
WO2011089166A119 Jan 201128 Jul 2011Virologik GmbhSemicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011089167A119 Jan 201128 Jul 2011Virologik GmbhKombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011100380A110 Feb 201118 Aug 2011Celgene CorporationArylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2011109345A11 Mar 20119 Sep 2011Axikin Pharmaceuticals, Inc.Isotopically enriched arylsulfonamide ccr3 antagonists
WO2011112689A29 Mar 201115 Sep 2011Ambit Biosciences Corp.Saltz of an indazolylpyrrolotriazine
WO2011112933A111 Mar 201115 Sep 2011Celgene CorporationMethods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
WO2011116161A217 Mar 201122 Sep 2011Axikin Pharmaceuticals Inc.Arylsulfonamide ccr3 antagonists
WO2011127019A25 Apr 201113 Oct 2011Celgene CorporationMethods for treating respiratory viral infection
WO2011127070A25 Apr 201113 Oct 2011Mannkind CorporationIRE-1α INHIBITORS
WO2011133520A119 Apr 201127 Oct 2011Synta Pharmaceuticals Corp.Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011133521A219 Apr 201127 Oct 2011Synta Pharmaceuticals Corp.Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
WO2011143147A110 May 201117 Nov 2011Celgene CorporationMethods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
WO2011146803A120 May 201124 Nov 2011Synta Pharmaceuticals Corp.Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
WO2011149824A123 May 20111 Dec 2011Synta Pharmaceuticals Corp.Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2011150183A126 May 20111 Dec 2011Ge Healthcare LimitedRadiolabeled compounds and methods thereof
WO2011150198A126 May 20111 Dec 2011Ambit Biosciences CorporationAzolyl urea compounds and methods of use thereof
WO2011150201A226 May 20111 Dec 2011Ambit Biosciences CorporationAzolyl amide compounds and methods of use thereof
WO2011153197A11 Jun 20118 Dec 2011Biotheryx, Inc.Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO2011153199A11 Jun 20118 Dec 2011Biotheryx, Inc.Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
WO2011156321A17 Jun 201115 Dec 2011Novomedix, LlcFuranyl compounds and the use thereof
WO2011159297A116 Jun 201022 Dec 2011Metabolex, Inc.Gpr120 receptor agonists and uses thereof
WO2012012370A119 Jul 201126 Jan 2012Summa Health SystemVitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012025217A123 Aug 20111 Mar 2012Algiax Pharmaceuticals GmbhNovel use of leflunomide and malononitrilamides
WO2012030885A131 Aug 20118 Mar 2012Ambit Biosciences CorporationHydrobromide salts of a pyrazolylaminoquinazoline
WO2012030894A131 Aug 20118 Mar 2012Ambit Biosciences CorporationThienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012030910A131 Aug 20118 Mar 2012Ambit Biosciences Corporation2-cycloquinazoline derivatives and methods of use thereof
WO2012030912A131 Aug 20118 Mar 2012Ambit Biosciences Corporation7-cyclylquinazoline derivatives and methods of use thereof
WO2012030913A131 Aug 20118 Mar 2012Ambit Biosciences CorporationAn optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030914A131 Aug 20118 Mar 2012Ambit Boisciences Corporation4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030917A131 Aug 20118 Mar 2012Ambit Biosciences CorporationAn optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030918A131 Aug 20118 Mar 2012Ambit Biosciences CorporationAdenosine a3 receptor modulating compounds and methods of use thereof
WO2012030924A131 Aug 20118 Mar 2012Ambit Biosciences CorporationAzolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030944A231 Aug 20118 Mar 2012Ambit Biosciences CorporationQuinoline and isoquinoline compounds and methods of use thereof
WO2012030948A131 Aug 20118 Mar 2012Ambit Biosciences CorporationQuinazoline compounds and methods of use thereof
WO2012037072A113 Sep 201122 Mar 2012Synta Pharmaceuticals CorporationHsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
WO2012044641A128 Sep 20115 Apr 2012Pathway Therapeutics Inc.1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A110 Oct 201119 Apr 2012Axikin Pharmaceuticals, Inc.Salts of arylsulfonamide ccr3 antagonists
WO2012055567A228 Oct 20113 May 2012Algiax Pharmaceuticals GmbhUse of malononitrilamides in neuropathic pain
WO2012064808A19 Nov 201118 May 2012Synta Pharmaceuticals CorpTetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
WO2012069658A225 Nov 201131 May 2012Sigmoid Pharma LimitedImmunomodulatory compositions
WO2012078492A15 Dec 201114 Jun 2012Celgene CorporationA combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2012078757A27 Dec 201114 Jun 2012Synta Pharmaceuticals Corp.Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A17 Dec 201121 Jun 2012Conatus Pharmaceuticals Inc.Solid forms of a phenoxybenzenesulfonyl compound
WO2012083017A215 Dec 201121 Jun 2012Celgene CorporationControlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012085648A121 Dec 201128 Jun 2012Purdue Pharma L.P.Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
WO2012096884A19 Jan 201219 Jul 2012Celgene CorporationPhenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
WO2012096919A110 Jan 201219 Jul 2012Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012106299A131 Jan 20129 Aug 2012Celgene CorporationPharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012109398A19 Feb 201216 Aug 2012Idenix Pharmaceuticals, Inc.Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012115723A16 Jan 201230 Aug 2012Medtronic, Inc.Emergency mode switching for non-pacing modes
WO2012116061A122 Feb 201230 Aug 2012Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitory compounds with radiotherapy
WO2012116247A124 Feb 201230 Aug 2012Synta Pharmaceuticals Corp.Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012121988A22 Mar 201213 Sep 2012Celgene CorporationMethods for treating diseases using isoindoline compounds
WO2012123353A19 Mar 201220 Sep 2012Algiax Pharmaceuticals GmbhNovel use of benzofuranylsulfonates
WO2012123406A112 Mar 201220 Sep 2012Algiax Pharmaceuticals GmbhNovel use of imidazotriazinones
WO2012125438A19 Mar 201220 Sep 2012Celgene CorporationSolid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2012125459A19 Mar 201220 Sep 2012Celgene CorporationMethods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2012125475A19 Mar 201220 Sep 2012Celgene CorporationUse of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
WO2012129237A220 Mar 201227 Sep 2012The University Of British ColumbiaTherapeutic agent for emphysema and copd
WO2012135160A127 Mar 20124 Oct 2012Pathway Therapeutics Inc.(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2012135166A127 Mar 20124 Oct 2012Pathway Therapeutics Inc.(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135175A127 Mar 20124 Oct 2012Pathway Therapeutics Inc.(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012141796A223 Feb 201218 Oct 2012Synta Pharmaceuticals Corp.Prostate cancer therapy with hsp90 inhibitory compounds
WO2012149251A127 Apr 20121 Nov 2012Celgene CorporationMethods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
WO2012149299A227 Apr 20121 Nov 2012Celgene CorporaitonMethods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2012151474A24 May 20128 Nov 2012Trustees Of Boston UniversityProton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
WO2012154321A130 Mar 201215 Nov 2012Centre National De La Recherche ScientifiqueCompounds and pharmaceutical compositions for the treatment of viral infections
WO2012158271A15 Apr 201222 Nov 2012Anadys Pharmaceuticals, Inc.Bridged polycyclic compounds as antiviral agents
WO2012162372A123 May 201229 Nov 2012Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
WO2012169934A131 May 201213 Dec 2012Asinex LimitedNovel kinase inhibitors
WO2012176061A121 Jun 201227 Dec 2012Purdue Pharma L.P.Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2012177678A220 Jun 201227 Dec 2012Celgene CorporationIsotopologues of pomalidomide
WO2013006864A29 Jul 201210 Jan 2013Synta Pharmaceuticals Corp.Treating cancer with hsp90 inhibitory compounds
WO2013014274A127 Jul 201231 Jan 2013Ge Healthcare Limited5ht1a antagonist useful for in vivo imaging
WO2013021276A19 Aug 201214 Feb 2013Purdue Pharma L.P.Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A17 Aug 201214 Feb 2013Celgene CorporationGene methylation biomarkers and methods of use thereof
WO2013024040A210 Aug 201221 Feb 2013B.S.R.C. Alexander FlemingTnf superfamily trimerization inhibitors
WO2013028505A117 Aug 201228 Feb 2013Synta Pharmaceuticals Corp.Combination cancer therapy of hsp90 inhibitor with antimetabolite
WO2013028880A123 Aug 201228 Feb 2013Cornerstone Therapeutics Inc.Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
WO2013039855A111 Sep 201221 Mar 2013Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A111 Sep 201221 Mar 2013Idenix Pharmaceuticals, Inc.Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013043967A121 Sep 201228 Mar 2013Celgene CorporationRomidepsin and 5 - azacitidine for use in treating lymphoma
WO2013049093A126 Sep 20124 Apr 2013Celgene CorporationCombination therapy for chemoresistant cancers
WO2013049332A127 Sep 20124 Apr 2013Infinity Pharmaceuticals, Inc.Inhibitors of monoacylglycerol lipase and methods of their use
WO2013056046A112 Oct 201218 Apr 2013Idenix Pharmaceuticals, Inc.Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056070A212 Oct 201218 Apr 2013Ambit Biosciences CorporationHeterocyclic compounds and methods of use thereof
WO2013067043A131 Oct 201210 May 2013Celgene CorporationMethods for treating cancers using oral formulations of cytidine analogs
WO2013067162A11 Nov 201210 May 2013Synta Pharmaceuticals Corp.Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013067165A11 Nov 201210 May 2013Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013071049A19 Nov 201216 May 2013Trustees Of Boston CollegeGramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2013074594A114 Nov 201223 May 2013Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013080036A130 Nov 20126 Jun 2013Purdue Pharma L.P.Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
WO2013084060A17 Dec 201213 Jun 2013Purdue Pharma L.P.Quaternized buprenorphine analogs
WO2013085902A14 Dec 201213 Jun 2013The University Of Texas M.D.Combination therapy methods for treating an inflammatory breast cancer
WO2013101926A127 Dec 20124 Jul 2013Allergan, Inc.Benzimidazole derivatives as selective blockers of persistent sodium current
WO2013103384A111 Jul 201211 Jul 2013Elcelyx Therapeutics, Inc.Biguanide compositions and methods of treating metabolic disorders
WO2013103919A25 Jan 201311 Jul 2013Elcelyx Therapeutics, Inc.Compositions and methods for treating metabolic disorders
WO2013126394A120 Feb 201329 Aug 2013Celgene CorporationSolid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
WO2013130600A127 Feb 20136 Sep 2013Ambit Biosciences CorporationSolid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A17 Mar 201312 Sep 2013Stichting Vu-VumcCompositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
WO2013138613A114 Mar 201319 Sep 2013Axikin Pharmaceuticals, Inc.3,5-diaminopyrazole kinase inhibitors
WO2013138617A114 Mar 201319 Sep 2013Axikin Pharmaceuticals, Inc.3,5-diaminopyrazole kinase inhibitors
WO2013142380A115 Mar 201326 Sep 2013The Regents Of The University Of CaliforniaOncovector nucleic acid molecules and methods of use
WO2013148857A127 Mar 20133 Oct 2013Synta Pharmaceuticals Corp.Triazole derivatives as hsp90 inhibitors
WO2013148864A127 Mar 20133 Oct 2013Andrei GudkovCuraxins for use in treating breast cancer and method for identifying patients likely to respond
WO2013152206A14 Apr 201310 Oct 2013Synta Pharmaceuticals Corp.Novel triazole compounds that modulate hsp90 activity
WO2013154878A13 Apr 201317 Oct 2013Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
WO2013156231A118 Mar 201324 Oct 2013Algiax Pharmaceuticals GmbhUse of imidazotriazinones in neuropathic pain
WO2013156232A118 Mar 201324 Oct 2013Algiax Pharmaceuticals GmbhUse of benzofuranylsulfonates in neuropathic pain
WO2013156850A117 Apr 201324 Oct 2013Purdue Pharma L.P.Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2013158928A218 Apr 201324 Oct 2013Elcelyx Therapeutics, Inc.Chemosensory receptor ligand-based therapies
WO2013167963A110 May 201314 Nov 2013Purdue Pharma L.P.Benzomorphan compounds as opioid receptors modulators
WO2013170159A110 May 201314 Nov 2013Synta Pharmaceuticals Corp.Treating cancer with hsp90 inhibitory compounds
WO2013177188A121 May 201328 Nov 2013Idenix Pharmaceuticals, Inc.3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A121 May 201328 Nov 2013Idenix Pharmaceuticals, Inc.3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177219A121 May 201328 Nov 2013Idenix Pharmaceuticals, Inc.D-amino acid compounds for liver disease
WO2014006215A15 Jul 20139 Jan 2014Sigmoid Pharma LimitedHydrogel vaccine formulations
WO2014020405A129 Jul 20136 Feb 2014Purdue Pharma L.P.Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
WO2014025960A18 Aug 201313 Feb 2014Celgene CorporationMethods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
WO2014030053A120 Aug 201327 Feb 2014Rhodes TechnologiesSystems and methods for increasing stability of dronabinol compositions
WO2014033530A127 Aug 20136 Mar 2014Rhodes Technologies1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014039748A16 Sep 201313 Mar 2014Axikin Pharmaceuticals, Inc.Isotopically enriched arylsulfonamide ccr3 antagonists
WO2014039960A19 Sep 201313 Mar 2014Celgene CorporationMethods for the treatment of locally advanced breast cancer
Classifications
U.S. Classification424/435, 424/449, 604/304, 401/132, 424/448
International ClassificationA61L15/58, A61L15/16, A61K9/70
Cooperative ClassificationA61K9/7061, A61L15/58, A61K9/7092, A61K9/7069
European ClassificationA61L15/58, A61K9/70E2B6D, A61K9/70E2B6B2, A61K9/70E2K